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Global incidence rate of breast cancer is on the rise and according to WHO 
GLOBOCAN report, today about 1.7 million women are diagnosed with the disease 
annually worldwide [1, 2]. In Singapore, breast cancer is the most common female 
cancer, accounted for approximately 29% of all cancer cases and attributed to 17% 
of cancer deaths among women in 2003-2007 [3].   
Breast cancer is a heterogeneous disease in terms of histopathological 
characteristics, response to treatment and clinical outcome, which makes 
prognostication rather challenging.  Survival has been improved in many developed 
countries over the last decades, partially owing to mammographic screening and 
improvement in diagnostic tools and treatment modalities.  The survival rate in 
many developing countries in Asia, however, remains relatively poor and 
prognostic tools developed in Western countries were shown to be inadequate or 
inappropriate for Asian population.  In this thesis, we propose four studies for 
different subgroups of patients to assess their outcome, evaluate prognostic factors 
and validate prognostic models.  
Many risk and prognostic factors have been identified for female breast cancer but 
how they affect disease risk and survival of male patients is uncertain.  In the first 
study of the thesis, we investigated breast cancer, diagnosed between 1970 and 
2007 from six population-based cancer registries. We found that the incidence of 
male breast cancer remained at a stable and low rate. However male patients 
presented with more advanced stages than women. After adjustment for age, stage 
and treatment, men had better relative survival than women.   
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The introduction of nationwide screening programme for breast cancer has 
dramatically increased the incidence of breast carcinoma in situ, a non-invasive 
malignant lesion. The second study in this thesis assessed prognosis of 8111 women 
with in situ breast cancer registered between 1980 and 2004 in the population-based 
Swedish Multi-Generation Register.  Women with carcinoma in situ were four 
times more likely to develop invasive breast cancer compared to women in the 
general population and the excess risk was more pronounced in younger women 
and those with family history.   
In the third study in this thesis, we validated CancerMath, a web-based prognostic 
tool, in patients with stage I to stage III breast cancer registered between 1990 and 
2011 in the Singapore Malaysia Hospital Based Breast Cancer Registry.  
Discrimination and calibration of CancerMath was modest and prediction was more 
accurate for patients with favorable tumor characteristics. In the fourth study, a 
systematic review was conducted to identify existing prognostic tools for de novo 
metastatic breast cancer.  We validated nine out of 16 models in 642 Asian women 
with de novo metastatic breast cancer diagnosed from 2000 to 2010 in the Singapore 
Malaysia Hospital Based Breast Cancer Registry.  The discriminatory performance 
of these models was modest.  The third and fourth studies suggest that development 
of Asian-specific prediction tools is needed to improve prognostication and to guide 
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Chapter 1 Background 
 
This chapter of the thesis summarizes what is known about breast cancer in terms 
of disease burden, classification, treatment and outcome of disease.  As this thesis 
focuses on prognostic research, a detailed literature review of prognostic indicators 
and multivariate prognostic tools developed for breast cancer patients is conducted 
here.   
1.1 Burden of the disease   
 
Breast cancer is the most common cancer among women in the world and is also 
one of the leading causes of cancer death among women according to GLOBOCAN 
2012 statistics published by the International Agency for Research on Cancer 
(IARC) of the World Health Organization (WHO).  In 2012, there were 1.7 million 
women diagnosed with breast cancer worldwide, which accounted for 11.9% of all 
new cancer cases that year[1].  The incidence of breast cancer is much higher in 
more developed regions comparing to less developed regions (Figure 1.1).  It varies 
from 27 per 100,000 in Middle Africa and Eastern Asia to 96 per 100,000 in 
Western Europe [4].  
Incidence has been rising in many parts of the world and the increment in Asia is 
more rapid than in the West, especially over the last decade (Figure 1.2) [5, 6].  
There is a steady decline in mortality in North American and European countries 
(Figure 1.3). In contrast, mortality in Asian and Latin American countries continues 
to increase.  As a result, the global mortality increased by 14% between 2008 and 
2012.  Models developed by the Cancer Intervention and Surveillance Modeling 
Network have demonstrated that decline in breast cancer death rate from 1975 to 
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2000 in the United States is attributed to both mammography screening and 
adjuvant therapy [7].  This may imply huge inequality in terms of early detection 
and access to healthcare between rich and poor countries. 
Figure 1.1 Estimated age-standardized rates (world population) per 100,000 
 
Source: Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo 
M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and 
Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: 
International Agency for Research on Cancer; 2013. Available from: 
http://globocan.iarc.fr, accessed on 1/12/2014. 
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 Figure 1.2 Trends in incidence of female breast cancer in selected countries: age-standardized rate (world population) per 100,000 
  
Source: Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, 
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 







Figure 1.3 Trends in mortality of female breast cancer in selected countries: age-standardized rate (world population) per 100,000 
   
Source: Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, 
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 
2013. Available from: http://globocan.iarc.fr, accessed on 1/12/2014.
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Although the incidence in Asia is still much lower than that in the Western 
populations, it is increasing rapidly, most likely due to the adoption of Western 
lifestyles, reproductive patterns and access to early detection [8]. Singapore has one 
of the highest breast cancer incidence rates in Asia [5]. According to the report 
published by the National Registry of Disease Office (NRDO) in 2012, the 
incidence has increased nearly threefold from 21.5 per 100,000 in 1971-1975 to 
60.7 per 100,000 in 2006-2010 [9].  One in 16 Singaporean women will develop 
breast cancer by age 75. The age-standardized mortality rate in Singapore increased 
from 8.5 per 100,000 in 1971-1975 to 13.5 per 100,000 in 1991-1995, but remained 
flat since then [9].  A study has estimated the period and cohort effects on breast 
cancer incidence in Singapore and Sweden, and found that cohort effect was much 
greater than period effect in Singapore, and was also more than what was observed 
in Sweden [8].  This finding implies that gradual change towards a more 
Westernized society in Singapore has contributed to the increasing incidence rate, 
especially for the more recent birth cohorts.     
Breast cancer in men is very rare, and only accounts for less than 1% of all breast 
cancer cases in Europe and the United States.  The incidence remained stable over 
the last few decades in Europe but increased recently in United States [10, 11] .   
Countries with higher incidence among women also have higher incidence among 








1.2 Risk factors for breast cancer 
 
Age 
The risk of breast cancer increases with age. The incidence rises rapidly until the 
age of 50 years, which corresponds to average age of menopause, and continues to 
increase at a slower rate.  The point of inflection in the age-specific incidence curve 
is known as the Clemmesen’s hook.  This pattern may be caused by the diminishing 
level of circulating estrogens after menopause [13].  Studies have suggested that 
breast cancer diagnosed in young (premenopausal) women is etiologically and 
biologically different from those in older (postmenopausal) women [14-17].  The 
effect sizes of several risk factors such as family history, obesity, weight gain and 
circulating endogenous estrogen vary between pre- and postmenopausal women [15, 
18-21]. Tumors in young women are more likely to be of large size, high grade and 
hormone receptor negative [22, 23].    
Comparing to Caucasian women, a higher proportion of Asian women are 
diagnosed at a younger age and premenopausal [5].  The peak age of onset in Asia 
is 45–50 years, whereas it is 60–70 years in the Western countries [24]. A study has 
found that the incidence rate of breast cancer among women younger than 45 years 
in Singapore become almost similar to that of Swedish women of similar age. In 
contrast, older women in Singapore had much lower incidence rate than their 
Swedish counterparts [8].  In the United States, a bimodal distribution of onset age 






The risk of breast cancer differs among ethnic groups due to differences in exposure 
of established risk factors and genetic profile.   In the United States, non-Hispanic 
White women have the highest incidence rate, while Asian American and Pacific 
Islander women have the lowest incidence [26].  In Singapore, incidence differs 
among the three major ethnic groups.  The age-standardized incidence rate in 
Singapore from 2006 to 2010 was 64.3 per 100,000, 58.7 per 100,000 and 61.4 per 
100,000 for Chinese, Malay and Indian women, respectively [9].  
Family history  
Approximately 15% of all breast cancer cases have a family history of breast cancer 
in first-degree relatives [27]. Women with a sister, a daughter or her mother 
diagnosed with breast cancer were twice as likely to develop breast cancer [28].  
The risk was much higher if multiple first-degree relatives were affected or a 
relative was diagnosed at a young age. Besides shared environmental risk factors, 
studies which compared the monozygotic and dizygotic twins have suggested that 
27% of the total risk of breast cancer can be explained by inherited genetic 
components [29]. High-penetrant germline mutations in BRCA1 and BRCA2 genes 
may account for 20% to 25% of inherited breast cancer cases and increase the 
lifetime risk of developing breast cancer to 40%-80% [30]. Relatively rare 
moderate-penetrant variants such as PALB2, ATM and CHEK may increase the 
lifetime risk of breast cancer by two-fold to 20% -50% [30].  A recent study 
published in the New England Journal of Medicine has concluded five to nine times 
increase in breast cancer risk to 33% -58% among PALB2 mutation carriers [31]. 
To date, 72 common low-penetrant breast cancer susceptibility variants, which are 
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found in more than 5% of in the population have been identified by genome-wide 
association studies (GWAS) [30].  The effect sizes of these common alleles are 
generally modest with odds ratios less than 1.5 [32].  If we assume the combined 
effect of these loci is multiplicative, the top 5% of female population with the 
highest genetic risk based on genetic profile have an approximately 2.3-fold higher 
risk than the average population [33].  All these identified low to high penetrant 
loci together explain approximately one-third of the familial risk of breast cancer 
[33].  
Mammographic density 
Mammographic density measures the relative area of epithelial and connective 
tissue in the breast, which is radiographically dense and appears white on a 
mammogram, while the area of fat tissue appears translucent.  Percent density, 
which is the dense area as a fraction of total breast area, is positively and almost 
linearly associated with breast cancer risk.  Women with high percent density (more 
than 75%) are four to five times more likely to get breast cancer than women with 
low density (less than 10%) [34].  And every one standard deviation increment in 
percent density will increased the breast cancer relative risk by 52% for 
premenopausal women and 53% for postmenopausal women [35]. The association 
is independent of other risk factors such as age and parity status, and 
mammographic density can predict breast cancer risk for over 10 years.  Comparing 
to percent density, absolute dense area is a weaker risk factor but still significantly 
associated with breast cancer risk after adjustment for confounders [35].   
Mammographic density gradually decreases with age and large decline in percent 




Breast cancer is a hormone-related disease. In particular estrogen has been shown 
to induce and promote mammary tumors. Certain reproductive factors that modify 
sex hormone levels, may also affect breast cancer risk.  For example, the ovaries 
start to produce steroid hormone at around the time of menarche and gradually 
reduce their function at menopause.  Women with earlier age at menarche or older 
age at menopause experience a longer period of increased level of circulating 
steroid hormone, and are thus more likely to develop breast cancer.  Breast cancer 
relative risk increases by 5% for each year decrease in age at menarche, and 3% for 
each year that menopause is delayed [38].  Parous women have a lower risk than 
nulliparous women and the younger a woman has her first full-term birth the lower 
her risk of breast cancer [39]. Breast-feeding for an extended period reduces breast 
cancer risk in premenopausal women [40].  
Hormone replacement therapy 
Hormone replacement therapy (HRT) is prescribed to women who suffer from 
menopausal symptoms caused by diminished circulating estrogen and progesterone 
levels. The Women's Health Initiative study and the Million Women Study 
published in 2002 and 2003 reported that HRT was associated with a 1.2-to 2-fold 
increase of breast cancer risk, especially among current users of combined estrogen 
and progestogen HRT [41, 42].  Since then the use of HRT has dropped, and the 
magnitude of decline ranged from 34% to 79% in Western countries [43].  
Consequently a few population-based studies also reported decline in breast cancer 
incidence rate between 2001 and 2006, ranging from 5% to 23% [43]. And such 
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decrease was only observed in women who were older than 50 years and more 
pronounced for estrogen receptor positive tumors [44].  
1.3 Early detection and diagnosis of breast cancer  
 
Physical examination 
The most common signs and symptoms of breast cancer include a lump in a breast, 
change in appearance of the breast or nipple.  During clinical breast examination, a 
health professional thoroughly palpates the breast and lymph nodes in the armpit 
and above the collarbones in a vertical strip pattern or a circular motion and inspects 
the breast and nipple for any changes of texture, shape and size.  If examination 
findings are suspicious of breast cancer, more tests will be performed to confirm 
the diagnosis. Although clinical examination may detect cancer that is missed by 
mammography, there is no randomized controlled trial (RCT) to assess its impact 
on mortality reduction [45-47]. Breast self-examination does not significantly 
reduce breast cancer mortality based on meta-analysis of two large RCTs [47]. 
Imaging tests  
Many women with early breast cancer do not have any symptoms. Therefore 
screening mammograms were introduced in many parts of world since 1980s, 
aiming to detect asymptomatic cancer at an early stage, thereby providing the 
opportunity for early intervention and better chance of survival.  In most of 
countries with nationwide or regional screening programmes, women aged 40-69 
are invited to screen from once a year to once every three years [48].  The 
participation rates vary between countries, from 18% in Japan to 87% in Finland 
[48]. The cost-effectiveness of a population-based screening programme by 
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mammography in Asia is debatable [49-51]. Thus far only high income countries 
in Asia such as Japan, Korea and Singapore have implemented such programmes. 
Opportunistic mammography screening by physician referral or self-referral is 
available in other Asian countries such as Hong Kong and Malaysia [52, 53].  In 
some European countries, both screening approaches co-exist and opportunistic 
screening is less sensitive and less cost-effective than organized screening 
programme [54-56].  
The most reliable evidence on the effect of mammographic screening comes from 
RCTs.  There have been 11 RCTs conducted in the 1970s and 1980s (Table 1.1), 
and a meta-analysis of 8 RCTs reported a 20% relative reduction in mortality for 
women who attended screening [57].  Another meta-analysis also found a relative 
risk of breast cancer mortality of 0.81 for the screened group compared to the 
control group and the difference was statistically significant [58]. However 
subgroup analysis suggested that the effect was not significant among women aged 
40-49 years.   
Negative findings on mortality reduction, potential risk of over-diagnosis and false 
positive results have generated controversies and debates over mammographic 
screening [59-61]. Over-diagnosis refers to diagnosis of indolent cancers which will 
not cause any symptom or death if left undetected and untreated. False positive 
mammograms lead to additional diagnostic tests, increase anxiety and decrease 
future screening participation [62-65]. Moreover screening misses interval cancers, 
which present between routine screens and are more aggressive and lethal [59]. The 
most recent publication from the Canadian National Breast Screening Study with 
25-year follow-up showed no mortality reduction and estimated 22% of screen 
detected cancers to be over-diagnosed [61].  In the mammography arm of this trial, 
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27% of cancers were interval cancers and the survival of patients with interval 
cancers was much worse compared to patients with screen detected cancers [61].  
An evaluation of 3 RCTs (Malmö I, Canada I and Canada II trials in Table 1.1) with 
relatively long follow-up and without screening invitation to the control group at 
end of the trial estimated the over-diagnosis to be 10% to 12% [57].    
Diagnostic mammograms are used to diagnose women with symptoms or abnormal 
results from screening mammogram. Compared to screening mammograms, 
diagnostic mammograms include views of the area of interest from multiple angles. 
Ultrasound and magnetic resonance imaging can be used along with mammography 
to provide additional information such as distinguishing a solid mass from a cyst 








Table 1.1 Characteristics of RCTs of breast cancer screening 
 New York 
HIP 
Malmö I and II Swedish Two 
County  
Canada I and II Stockholm Göteborg UK Age trial Edinburgh  
Start Year 1963 1976 1977 1980 1981 1982 1991 1978 
Number of 
women  
62,000 60,076 133,065  89,835 60,800 52,222 160,921 54,654 
Age group  40-64 45-69 and  
43-49 
38-75 40-49 and 
50-59 
39-65 39-59 39-41 45-64 
Invited group 
intervention 








3 12 7 5 4 7 8 6 
Attendance 65% 74% 85% 88% 82% 84% 81% 65% 
Control group 
intervention 
None None None PE+SE None None None None  
M: Mammography  PE: Physical examination   SE: self-examination  
Source: Independent UK Panel on Breast Cancer Screening, The benefits and harms of breast cancer screening: an independent review. Lancet, 




All lesions suspicious of breast cancer need tissue confirmation. Cells or tissue from 
the suspicious area can be obtained by fine needle aspiration cytology or core 
biopsy.  The collected sample is examined by a (cyto)pathologist for presence of 
malignant cells. Fine needle aspiration which uses narrower gauge needle is less 
invasive and the result is available immediately. Core biopsy provides architectural 
information in diagnosing invasive cancer and obtains more tissue to allow test for 
receptor status. Both methods are well-established with high degree of sensitivity 
and specificity. The false positive rate is less than 1% and false negative rate is 
about 3%-24% for fine needle aspiration cytology and 1%-2% for core biopsy [66]. 
Ultrasound, mammography or magnetic resonance imaging is used to guide the 
needle into the correct area.  
1.4 Clinical characteristics and prognostic factors  
Breast cancer is a heterogeneous disease and can be classified based on the 
histological type, grade, stage and expression of molecular or genetic tumor 
markers.   These factors can be used for prognostication and selection of proper 
treatment.  
Histological type 
Breast cancer can originate from different types of tissue within the breast. Nearly 
all breast cancers start from the glandular tissues of the breast, such as the ducts and 
lobules. If the cancerous cells have not invaded through the basement membrane, it 
is defined as carcinoma in situ. Otherwise, it is defined as invasive or infiltrating 
carcinoma. Ductal carcinoma begins in the lining of a milk duct and is the most 
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common type of invasive and in situ breast cancer.  About 70-73% of invasive 
diseases are invasive ductal carcinoma (IDC) [27]. Ductal carcinoma in situ (DCIS) 
is a pre-cancerous condition and has the potential to invade and become invasive 
cancer over time. Invasive lobular carcinoma (ILC) begins in the milk-producing 
lobules and is the second most common type of breast cancer, accounting for 13%-
16% of invasive tumors.  Lobular carcinoma in situ (LCIS) is not considered a 
cancer but a risk indicator for developing invasive breast cancer later on. Compared 
to IDC, ILC is less likely to present as a discrete mass, and therefore more difficult 
to be detected by mammography and palpation [67].  The difference in growth 
pattern can be explained by loss of E-cadherin expression frequently observed in 
ILC and LCIS tumors [68]. Expression microarray analysis has also identified a 
few genes expressed differently between ductal and lobular tumors. Although ILC 
is usually diagnosed at a later stage, the prognosis of ILC patients is better than IDC 
patients after adjustment for stage as ILCs are more likely to be hormone receptor 
positive [69].  However the prognostic advantage of ILCs disappears at 
approximately 6 years after diagnosis [70].  IDC and ILC also have distinct 
metastatic pattern. IDC is more likely to spread to lung and brain, while ILC 
commonly spreads to the gastrointestinal tract, gynaecological organs and 
peritoneum [71, 72]. 
Besides ILC and IDC, the remaining approximately 15% of invasive tumors 
comprise special types of breast carcinoma such as tubular, mucinous, medullary 
and papillary carcinoma.  The cancer cells of these special types have different sizes, 
shape or growth pattern and each subtype accounts for less than 4% of all breast 
cancers [73, 74]. Rarely breast cancer can begin in the connective and support tissue 




The grade of tumor describes how different the cancer cells are from normal cells 
in size and shape and how fast the cancer cells are growing when viewed under a 
microscope. Tumor grade is commonly evaluated according to the Elston-Ellis 
modification of Scarff-Bloom-Richardson grading system (Nottingham Combined 
Histologic Grade) [75, 76]. In this system, percentage of glandular/tubular 
formation, the variation in size and shape of the nuclei (nuclear pleomorphism) and 
the number of dividing cells (mitotic activity) are taken into consideration and each 
element is given a score of 1 to 3 by the pathologist.  The total score from the three 
components is further classified into three levels. Grade 1 or low grade tumor 
indicates well-differentiated cancer cells that are similar to normal cells and slow-
growing, grade 2 or intermediate grade tumor composes of moderately-differently 
cancer cells and poorly-differentiated cancer cells which are completely different 
from normal cells, and fast-growing are categorized as grade 3 or high grade.  
Higher grade tumors grow and spread more rapidly, and are associated with 
increased risk of distant recurrent and poorer survival [77].  This association is 
independent of other predictors for survival such as tumor size and lymph node 
involvement [77]. 
Stage  
The stage of breast cancer describes the extent to which the disease has spread and 
is determined by size of the tumor (T), number of lymph nodes carrying metastases 
(N) and presence of distant metastases (M).  An overall stage 0-IV can be assigned 
to breast tumor when T, N and M are combined.  This TNM staging system was 
first introduced by Union for International Cancer Control and then adopted by 
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American Joint Committee on Cancer (AJCC).  The first edition of AJCC Manual 
for Staging of Cancer was published in 1977.  Since then several changes have been 
made over time and the latest seventh edition was published in 2011.  Some of the 
major changes from sixth edition to seventh edition included classification of small 
tumors with exclusively micrometastasis in lymph nodes as stage IB and creation 
of M0 (i+) category.  Patients with metastasis in supraclavicular lymph node were 
considered N3 before 1987 and were re-classified as M1 in the fifth edition of AJCC 
staging system.  The sixth edition, published in 2002, revised the classification of 
isolated ipsilateral supraclavicular metastasis from M1 (stage IV) to N3c (stage 
IIIC). Several studies have confirmed that survival of this group is more similar to 
locally advanced breast cancer rather than breast cancer with distant metastasis [78-
80].  TNM staging can be based on physical examination, imaging test and 
laboratory results before initiation of treatment (clinical stage) or based on 
pathological examination of resected tumor and lymph nodes following surgery.  
Prefix “yc” and “yp” should be used for clinical and pathologic TNM stage 
evaluated after neoadjuvant treatment.  
Tumor size and lymph node involvement are the strongest prognostic indicators for 
non-metastatic breast cancer and larger tumor size is also correlated with more 
involved lymph nodes [81]. The prognostic effect of tumor size is independent of 
nodal status and is shown for all stages including node-negative disease.  A study 
found that 1cm decline in tumor size was associated with a 2.5% reduction in 15-
year mortality and 1.5cm decline was associated with 10.8% reduction among node-
negative patients.  The impact was much greater for node-positive patients with 
10.3% reduction for 1cm decline and 23% for 1.5cm decline [82].  Breast cancer 
patients with lymph node involvement had four to eight times higher mortality than 
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node-negative patients, and the risk increased with increasing number of positive 
lymph nodes [81].  
Many cancer registries such as the Surveillance, Epidemiology, and End Results 
(SEER) Program also use localized, regional and distant staging system, which is 
determined by whether the cancer is confined within the organ of origin (localized), 
has spread to surrounding organs or tissues or lymph nodes (regional) or has spread 
to distant tissues or organs or to distant lymph nodes (distant) [83].  According to 
18 population-based cancer registries in the SEER database in the United States, 
61% of invasive cases were diagnosed at localized stage, 32% and 5% were 
diagnosed at regional and distant stage respectively in 2004-2010.  Due to 
introduction of screening programme and increased awareness of breast cancer, 
more breast cancers are detected at an early stage.  However women in developing 
countries and women with lower socioeconomic status are still more likely to be 
diagnosed at later stages [84].   
Survival of breast cancer patients varies by stage.  The 5-year and 10-year survival 
of stage 0 (i.e. DCIS) patients is 99% and 98% respectively while stage IV (i.e. 
metastatic) breast cancer patients have 5-year survival of less than 25% and 10-year 
survival of approximately 7%.   
Receptor status and molecular subtypes 
Hormone receptors are proteins, to which specific hormone such as estrogen and 
progesterone will bind, thereby promoting the growth of cells.  For breast cancer, 
the presence of estrogen receptor (ER) and progesterone receptor (PR) will affect 
the prognosis and treatment of cancer.  ER positive breast cancer, which depends 
on estrogen to grow, can be treated with hormone therapy such as tamoxifen and 
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aromatase inhibitors or ovarian suppression or ablation for pre-menopausal women, 
aiming to prevent estrogen from binding to receptor or to reduce the production of 
estrogen.  A meta-analysis of RCTs confirmed that tamoxifen for 5 years reduces 
recurrence and mortality risk for ER+ but not for ER- breast cancer [85].  Even 
without adjuvant systemic treatment, patients with ER+ tumor have been shown to 
have better disease-free survival and overall survival in NSABP B-06 trial [86]. The 
presence of PR is strongly correlated with ER status and is an independent predictor 
for benefit from adjuvant hormone therapy among ER+ patients [87].   In the SEER 
database,  63% of patients were ER+/PR+ and the remaining cases were ER+/PR- 
(13%), ER-/PR+ (3%) and ER-/PR- (21%) [88]. Comparing to ER+/PR+ tumor, 
women with ER+/PR-, ER-/PR+ and ER-/PR-  tumor had 1.4-, 1.8- and 2.3-fold 
increased relative risk of death respectively [88].  Hormone receptor status is 
evaluated by pathologists, using immunohistochemistry (IHC) to determine 
percentage of stained tumor cells.  Historically, a cut-off value of 10% was used to 
define ER or PR positivity.  However, a few studies reported treatment response 
among patients with as low as 1% of cells stained positive [89]. In 2010, the 
American Society of Clinical Oncology and College of American Pathologists 
recommended 1% threshold to allow more patients eligible for hormone therapy 
[89]. 
Overexpression of human epidermal growth factor 2 (HER2) protein is associated 
with more aggressive tumor behavior, higher risk of recurrence and poorer survival, 
especially among node positive patients [90, 91].  It is caused by amplification of 
the HER2 gene which can be found in 15-20% of patients with breast cancer [92, 
93]. It can be assessed by either IHC to check for over-expression of HER2 protein 
or fluorescence in situ hybridization (FISH) to determine the amplification of HER2 
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gene. IHC test gives a score of 0 to 3+, based on staining intensity.  The score can 
be interpreted as HER2 positive (3+),  HER2 negative (0 or 1+) or equivocal (2+). 
FISH test provides the copy number of HER2 gene per nucleus or the ratio of HER2 
to chromosome enumeration probe 17 (CEP17). According to Food and Drug 
Administration (FDA), cut-off value of four copies per nucleus or HER2/CEP17 
ratio of 2 is used to define HER2 positivity [94].   HER2 overexpression used to be 
associated with a worse outcome. It is a predictive biomarker for response to 
chemotherapy, hormone therapy, and most importantly for HER2-targeted therapy 
such as trastuzumab and lapatinib.  Use of trastuzumab has been shown to 
significantly improve overall survival and disease-free survival in HER2 positive 
breast cancer at all stages [95, 96].  Today, HER2 positivity is associated with 
improved outcome if treated with targeted therapy. The American Society of 
Clinical Oncology and College of American Pathologists recommend testing all 
newly diagnosed invasive breast cancers for HER2 status using either IHC or FISH 
[97].   
Using DNA microarray analysis, researchers have found that breast cancer can be 
categorized into several subgroups based on gene expression profile of the tumor. 
The five major subtypes are luminal A, luminal B, HER2-overexpressing, basal-
like and normal-like and they are associated with different outcomes.  Joint ER, PR 
and HER2 status, and expression of three other biomarkers Ki-67, cytokeratin (CK) 
5/6 and epidermal growth factor receptor (EGFR) are often used as surrogates of 
molecular subtypes as shown in Table 1.2 [27, 98, 99].   Triple negative breast 
cancers defined by absence of ER, PR and HER2 are more aggressive and have 
higher risk of recurrence and death due to lack of targeted therapy [100]. It is more 
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prevalent among premenopausal women and among women of African and South 
Asian descent than non-Hispanic whites [101-103].    















































Distribution 55-65% 7-12% 6-10% 10-15% 5-10% 
Grade 
1 and 2 42% 44% 30% 18% 19% 
3 58% 56% 70% 82% 81% 
Stage 
I 44% 39% 28% 24% 48% 
II 47% 54% 53% 62% 39% 









Source: Phipps, A.I. and C.I. Li, Breast Cancer Biology and Clinical Characteristics, 
in Breast Cancer Epidemiology, C.I. Li, Editor. 2010, Springer Science+Business 
Media.  
 
Multiple genomic assays such as Oncotype DX and MammaPrint have been 
developed to estimate risk of recurrence for early breast cancer [104]. MammaPrint 
was developed based on expression of 70 genes within a tumor and can identify 
women in whom chemotherapy can be safely omitted [105]. OncotypeDX, which 
was developed based on 21 genes, can be used to predict benefit from hormone- 






Many studies suggested that breast cancer diagnosed in young women (less than 35 
years old) is biologically more aggressive (high grade, ER- and HER2+ tumors) 
than that in older women and young women are often diagnosed at a later stage.  As 
a result prognosis is much poorer in terms of both survival and recurrence [107-
111].   The negative prognostic effect of young age was also observed among 
premenopausal breast cancer [112, 113], while among postmenopausal women, 
older age was associated with higher mortality risk in stage I and II disease but not 
in stage III and IV disease, after adjustment for comorbidities [114].  Disease-
specific mortality also increased with increasing age after adjustment for treatment 
and tumor characteristics in a study on postmenopausal hormone receptor positive 
breast cancer [115].  Two population-based studies in Singapore and Sweden found 
the highest relative survival among women to be between 40 and 49 years old [116, 
117]. A Swedish study investigated the contribution of various determinants to the 
survival discrepancy between different age groups and concluded that tumor 
characteristics rather that treatment activity was the most important explanatory 
variable [118].  
Comorbidity 
Comorbid chronic conditions such as hypertension, diabetes and heart disease are 
often present at time of diagnosis of breast cancer, especially among elderly patients. 
In the SEER database, the most common comorbidities among women aged 65 and 
above were previous cancer (16%), diabetes (13%), chronic obstructive pulmonary 
disease (9%) and congestive heart failure (7%) [119]. Patients with comorbidities 
were less likely to receive radiotherapy or have axillary dissection if they underwent 
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lumpectomy in a Dutch study [120].  Many studies have reported that comorbidities 
are associated with poorer prognosis among breast cancer patients regardless of age 
and stage when they are measured using index or a sum of the number of conditions 
[121, 122].  However the effect of each individual type of comorbidity varies and 
whether it affects breast-specific mortality is uncertain.  For example, diabetes was 
found to be significantly associated poor total and non-breast cancer mortality, but 
its effect on recurrence or breast cancer-specific mortality was not consistent across 
studies [123-125].  Studies also found liver disease, chronic renal failure, dementia, 
and congestive heart failure were the most significant conditions for overall 
mortality [119, 120].  
Gender  
Men are more likely to be diagnosed with breast cancer at an older age and more 
advanced stages as compared to women [126, 127].  However there are conflicting 
findings whether male and female patients have comparable survival after 
adjustment for age and stage. An important confounding factor would be difference 
in underlying life expectancy between men and women.  Two population-based 
studies reported that although the overall survival of male breast cancer is poor for 
all stages, survival differences disappear after adjustment for background mortality 
rate, especially for early stage breast cancer [11, 126].    
1.5 Treatment for breast cancer  
 
Locoregional therapy   
The goal of locoregional therapy for early breast cancer is to eradicate all malignant 
breast tissue in the breast and lymph nodes to achieve optimal local control with 
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surgery and radiotherapy [128].  The Early Breast Cancer Trialists’ Collaborative 
Group has suggested that adequate local treatment can reduce 15-year breast cancer 
mortality by 5.2% by avoiding local recurrence [129].  Surgical removal of the 
primary tumor in breast includes either mastectomy or breast-conserving surgery.  
Whole breast irradiation is routinely given after breast-conserving surgery.  Several 
RCTs with 20-year follow up have showed that long term distant-disease-free 
survival and overall survival among women who undergo breast-conserving 
surgery followed by irradiation is the same as that among women who undergo 
radical or total mastectomy [130-132].   However the incidence of recurrence in the 
ipsilateral breast is significantly higher in women treated with breast-conserving 
surgery than in those treated with mastectomy. Radiotherapy after breast-
conserving surgery reduces locoregional and distant recurrence, and breast cancer 
death [133].  Most patients with a unifocal tumor and adequate tumor to breast size 
ratio are considered suitable for breast-conserving surgery [134].  For patients with 
multicentric disease and those who are unlikely to achieve negative surgical 
margins, mastectomy is the treatment of choice. Post-mastectomy radiotherapy may 
reduce recurrence and mortality in patients with high risk disease (i.e. large tumors, 
high nodal burden) [129, 135].  
Axillary lymph node dissection (ALND) was the standard surgical procedure to 
remove lymph nodes in the axilla to evaluate the extent of disease (stage) [136, 137].  
The survival benefit of ALND for clinical node negative patients remained 
controversial, given the evidence against ALND from NSABP B-04 trial and 
evidence from a meta-analysis of 6 RCTs which showed improvement in overall 
survival [138, 139].  Recent RCTs have reported that ALND, which is associated 
with complications such as lymphedema, pain and seroma, is unnecessary if cancer 
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is not present in the sentinel lymph node (SLN) [140-142].  SLN is defined as the 
hypothetical first lymph node(s) to which cancer cells will spread from a primary 
tumor and can be located by injection of radioactive substance or/and a blue dye 
near the tumor.  SLN dissection has been widely accepted as staging tool due to 
lower morbidity. The Z0011 trial conducted by the American College of Surgeons 
Oncology Group found that ALND did not improve overall or disease-free survival 
even for positive SLN patients with T1-T2 tumor and treated with lumpectomy, 
whole breast irradiation and adjuvant therapy [143].  These findings have changed 
current practice in many parts of Europe.   
For metastatic breast cancer, resection of the primary tumor is not recommended 
except for patients with symptomatic local breast or chest wall tumors [144]. Recent 
observational studies have suggested that surgical treatment of primary tumor could 
improve survival of patients with de novo metastatic breast cancer [145].  However 
it is difficult to sufficiently control for potential confounding by indication in these 
studies. The preliminary result from RCT conducted at Tata Memorial Hospital in 
Mumbai, India did not show any survival benefit of surgery in patients with de novo 
metastatic breast cancer [146].  
Systemic therapy  
Unlike local therapy which focuses on the primary tumor, systemic therapy aims to 
eliminate micrometastasis or microscopic tumor cells that have spread beyond the 
breast and nearby lymph nodes to the entire body.  Systemic therapy consists of 
chemotherapy, hormonal therapy, and targeted therapy and can be given before or 
after locoregional treament (called neoadjuvant and adjuvant therapy, respectively).  
For early breast cancer, adjuvant therapy is more likely to be administered to 
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patients with higher risk of relapse or death, which can be determined based on 
prognostic factors discussed earlier (age, stage, receptor status etc.).  Adjuvant 
tamoxifen, a hormone therapy drug for hormone receptor positive breast cancer 
reduces the relative risk of breast cancer death by 31% for ER+ breast cancer [147].  
Five-year use is significantly more effective than use for 1-2 years [147].  
Aromatase inhibitors (AI), another hormone therapy drug, gained popularity among 
postmenopausal women due to its greater effect in recurrence reduction [148].  
Survival benefit of hormonal treatment is seen in the absence of chemotherapy and 
is still present, although less substantial when combined with chemotherapy.  For 
adjuvant chemotherapy, multiple cytotoxic drugs are given in combination 3-4 
weekly for four to six cycles. The Early Breast Cancer Trialists’ Collaborative 
Group review published in 2005 has shown that second generation anthracycline-
based polychemotherapy reduced annual breast cancer mortality by 38% for women 
younger than age 50 and 20% for women aged 50-69, and was more effective than 
first generation alkylating-based CMF (cyclophosphamide, methotrexate, 
fluorouracil) chemotherapy [147]. A review published in 2012 confirmed that the 
third generation taxane-plus-anthracycline-based regimens slightly but 
significantly improved outcome in comparison with an anthracycline-based control 
regimen [149].  And the proportional reduction in recurrence and breast cancer 
mortality due to taxane-based regimens or anthracycline-based regimens was 
independent of age, nodal status, tumor size, grade and ER status [149].  Adjuvant 
trastuzumab, the first targeted therapy for HER2+ cancer, was introduced to early 
breast cancer after robust result were observed in metastatic breast cancer setting. 
A meta-analysis of 5 RCTs published in 2008 demonstrated lower mortality and 
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recurrence risk among non-metastatic patients who received adjuvant trastuzuma 
and chemotherapy versus patients who received chemotherapy alone[150].   
Systemic therapy can also be given to locally advanced disease before surgery to 
make inoperable tumor operable.  For early stage breast cancer, neoadjuvant 
systemic treatment increases the likelihood of receiving breast-conserving surgery 
instead of mastectomy by shrinkage of tumor. Survival is not affected by timing of 
chemotherapy (i.e. neoadjuvant versus adjuvant) [151].  For patients with hormone 
receptor positive tumors and are unfit for chemotherapy, neoadjuvant hormone 
therapy can be considered [152].  For patients with HER2+ tumors, addition of 
targeted therapy has shown better result than chemotherapy alone [153]. 
Pathological complete response (pCR) after neoadjuvant treatment is strongly 
associated with disease-free survival and overall survival. Therefore it is commonly 
used as an intermediate endpoint in clinical trials [154].  The three most common 
definitions of pCR are 1) absence of invasive cancer and in-situ cancer in the breast 
and axillary nodes, 2) absence of invasive cancer in the breast and axillary nodes, 
irrespective of DCIS, and 3) absence of invasive cancer in the breast irrespective of 
DCIS or nodal involvement [155].  The prognostic value of pCR is dependent of 
receptor status and grade, as the strongest association was found in the aggressive 
subtype [155, 156].  
For patients with metastatic breast cancer at presentation, the goal is to palliate 
symptoms and prolong life since cure is highly unlikely. For these patients, 
systemic therapy is the mainstay of treatment. Hormone therapy is the preferred 
initial treatment for ER+ and/or PR+ tumor unless there are symptomatic 
metastases at visceral organs, for which chemotherapy will be given.  Unlike early 
breast cancer, single agent chemotherapy is preferred over polychemotherapy 
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regimen for most metastatic patients except for those with rapid progression or life-
threatening visceral metastases [157]. For recurrence at distant sites, there is high 
chance of drug resistance to previously administered chemotherapy or hormone 
therapy.   
Adverse effects of treatment  
Although tremendous advances in systemic treatment have contributed to 
considerable improvement in breast cancer outcome, many patients experience 
short-term and long-term adverse effects caused by the treatments.  Common short-
term complications include nausea and vomiting, mucositis, neutropenia, 
myelosuppression and fatigue, which occur during the course of treatment [158].  
Long-term side effects such as cardiac toxicity, bone fracture, secondary cancer, 
cognitive impairment, menopausal symptoms and infertility may impair the patients’ 
quality of life,  years or even decades after completion of treatment [159, 160].  
Breast surgery, ALND and radiotherapy may also cause seroma, fibrosis, 
lymphedema, and cardiovascular disease [161].   
 1.6 Breast cancer prognosis  
 
Locoregional recurrence and distant relapse  
Breast cancer can relapse after initial treatment, impairing survival.  The most 
common sites of relapse are listed in Table 1.3. The suspicion of relapse is 
confirmed by imaging tests such as ultrasound, computed tomography, magnetic 
resonance imaging and positron emission tomography. Studies conducted before 
the widespread use of breast-conserving surgery and systemic therapy have shown 
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that distant metastasis to skeleton is the most frequent site of first relapse, followed 
by locoregional recurrence and pulmonary metastasis [162].  Pattern of spread can 
differ by histological types and receptor status. IDC is more likely to spread to lungs 
and brain and ILC commonly spreads to the gastrointestinal tract, gynaecological 
organs and peritoneum [163]. Distant metastasis of ER- disease is more likely to be 
seen in soft tissues such as lungs, liver and brain and patients with HER2 positive 
tumors have an increased risk of brain metastasis [164].  In the study of recurrence 
in patients enrolled in seven Eastern Cooperative Oncology Group trials, 45% 
experienced recurrence with a peak incidence between 1 and 2 years after diagnosis, 
followed by a decrease [165].  The rate of decrease was much slower from five 
years onwards as compared to from 2nd to 5th year.  For breast carcinoma in situ, the 
risk of subsequent ipsilateral invasive breast cancer is higher while the risk of 
distant metastasis is still low [162].    
Table 1.3 Most common sites of breast cancer relapse. 
Type of relapse Location  
Local recurrence  Ipsilateral breast (breast conserving surgery) or 
chest wall (mastectomy) including skin and 
subcutaneous tissue, surgical scar and biopsy tract  
Regional recurrence Ipsilateral lymph nodes (axillary, supraclavicular, 
infraclavicular, internal mammary, and 
intramammary). 
Distant recurrence   Contralateral lymph nodes (axillary, 
supraclavicular, infraclavicular, parasternal, and 
internal mammary) in absence of 
synchronous ipsilateral or contralateral breast 
malignancy or distant metastasis,  
skin and subcutaneous tissue outside the 
ipsilateral chest wall, 
bone, lung, liver and central nervous system 
Source: Moossdorff M et al, Maastricht delphi consensus on event definitions for 
classification of recurrence in breast cancer research. J Natl Cancer Inst. 2014 Nov 




Second primary cancer 
Breast cancer survivors have a 2- to 6-fold increased risk of developing a second 
cancer in the contralateral breast as compared to healthy women developing a first 
breast cancer [166].  Their risk of developing a second non-breast primary cancer 
is 25% higher [167].  For DCIS patients, their risk of developing subsequent 
invasive or in situ breast cancer in the contralateral breast is also higher than the 
general population [168, 169]. Risk factors for contralateral breast cancer include 
family history, age at first diagnosis and ER status of first tumor [170].  Women 
with bilateral breast cancer have higher mortality compared to women with 
unilateral disease. The risk increases further if the time interval between the first 
and second cancer is shorter [171].  For other secondary cancers, the increased risk 
at sites such as esophagus, lungs, stomach and soft tissues might be consequences 
of radiation used to treat breast cancer [167].  Certain cytotoxic drugs for breast 
cancer have been shown to associate with higher risk of acute myeloid leukemia, 
and tamoxifen increases the risk of endometrial cancer [172]. Increased surveillance 
and shared genetic and environment risk factors may also play a role in the 
increased risk of secondary cancer [173].   
Survival 
The 5-year overall survival of breast cancer was 67.9% in Singapore in 2003-2007 
[174].  Compared to the general population, the 5-year age-standardized relative 
survival (ASRS) was 76.4% during the same period [174].  The estimate in 
Singapore was slightly lower than high-income countries such as the United States, 
Sweden, Japan, Finland and Australia, where the ASRS was more than 80% [175]. 
The ASRSs in middle and low-income countries were less than 60% and less than 
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40% respectively [175].  Due to advances in early detection and treatment, relative 
survival in many countries has improved over time.  In England and Wales, 1-year 
relative survival increased from 82% in 1971-1975 to 96% in 2005-2009 and 5-year 
relative survival increased from 52% to 85% [176, 177]. A similar trend has also 
been observed in Singapore, where 5-year ASRS increased from 49% in 1973-1977 
to 76% in 2003-2007.  
There are remarkable ethnic and socioeconomic disparities in survival after breast 
cancer [175, 178-180].  In the United States, African American patients have 
significantly worse survival than Caucasian women after controlling for differences 
in socioeconomic status [181]. Other ethnic groups such as Latinas and Pacific 
islanders have intermediate prognosis compared to African and white Americans, 
whereas survival in Asian Americans varies among different subpopulations and by 
immigrant status [182, 183]. In Singapore and Malaysia, Malay ethnicity is 
associated with poorer outcome compared to the other two major ethnic groups, 
namely, Chinese and Indians, after adjustment for age, stage and tumor 
characteristics [178].  The ethnic disparities in survival can be explained by 
differences in life expectancy, comorbidities, socioeconomic status, tumor biology, 
response to treatment, and lifestyle before and after diagnosis. A review on 
socioeconomic differences in cancer survival was conducted by IARC in 1997 and 
it showed that female breast cancer was one of the cancer sites with the widest 
differences, regardless of which measure of socioeconomic status was used [184].  
Poorer survival of patients from lower socioeconomic status can be explained by 
poorer access to health care, leading to late presentation with more advanced stages 




Multivariate prognostic tool  
As described in the previous sections, breast cancer is a complex and heterogeneous 
disease with various treatment options.  Accurate prognostication is important for 
clinicians and for patients to benefit the most from adjuvant therapy and spare them 
from toxic side effects, reduce financial burden, and to let them have an idea about 
life expectancy.   Many prognostic tools have been developed to estimate risk of 
recurrence and death as well as added benefit from specific type of treatment.  These 
tools include predictors such as traditional clinicopathologic factors (age, tumor 
size and number of positive nodes etc.) and/or gene expression profile of the tumor 
and novel biomarkers. The selection of predictors and statistical/mathematical 
algorithms used to combine their effect size vary between different prognostic tools. 
A systematic review published in 2014 compared the characteristics of several risk 
prediction models for non-metastatic breast cancer (Table 1.4) [185].   
The most widely used prognostic models are the Nottingham Prognostic Index 
(NPI), Adjuvant! Online, MammaPrint and OncotypeDx, and they have been 
validated in different populations.  NPI, introduced in 1982, was the first prognostic 
model for breast cancer patients. It includes only tumor grade, size, and nodal status 
for prediction of disease-free survival, and can be calculated as 0.2×Size (cm)+ 
lymph node stage (1-3) + grade (1-3) [186, 187]. A higher score indicates worse 
survival and the score is usually split into three to five subgroups. The widely used 
Adjuvant! Online (www.adjuvantonline.com) (Figure 1.4) is a software model, that 
calculates 10-year overall survival and disease-free survival of patients with non-
metastatic breast cancer, based on a patient’s age, tumor size, grade, ER status, 
nodal status, and comorbidities. It also quantitatively predicts the absolute gain 
from adjuvant therapy [188]. CancerMath (http://www.lifemath.net/cancer/) 
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(Figure 1.5) is the latest web-based calculator, which takes HER2 status into 
account when estimating overall survival for each of the first 15 years after 
diagnosis [189]. It was established based on the binary biological model of cancer 
metastasis and the parameters of the mathematical equation were derived from the 
SEER database in the United States.  It was shown to be accurate and comparable 
with Adjuvant! Online [189].  Most of these models were accurate in populations 
similar to its derivation dataset and were able to stratify patients into low, moderate 
and high risk groups [185].  Adjuvant! Online was associated with 0.9% to 12.7% 
change in treatment recommendation in four prospective studies [190]. Although it 
was recommended by the National Institute for Health and Clinical Excellence and 
widely used by oncologists [191-194], several validation studies suggested that 
Adjuvant! Online was suboptimal in women younger than 40 years and older than 
75 years [195, 196]. The model was recently validated in Malaysia, Korea, and 
Taiwan, where it was shown to substantially overestimate actual survival [197-199]. 
The underperformance can be attributed to different underlying mortality risk, 
proportion of advanced disease, tumor biology, response to treatment, and lifestyle 
after diagnosis between US population and study populations [200-202].  
Patients tend to misunderstand the results provided by these tools [203]. Studies 
have found that prognostic assessment may cause anxiety and distress among 
patients [203, 204].  Therefore clear and simplified illustration with graphic 






Table 1.4 Summary of risk prediction models 
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2011 US RFS GP, 200 genes  Micro-
array 
BCCS, breast cancer specific survival; OS, overall survival; RFS, recurrence-free 
survival; Tx, treatment; GP, genetic profile; IHC, immunohistochemistry panel; Tm 
tumor size; N, nodal status; LVI, lymphovascular invasion 
Source:  Engelhardt, E.G., et al., Predicting and communicating the risk of 
recurrence and death in women with early-stage breast cancer: a systematic review 















Figure 1.4 Screenshot of Adjuvant! Online 
 
 








Chapter 2 Aims and objectives of the thesis  
 
The overall aim of the thesis is to determine long term survival among different 
subgroups of breast cancer patients, to evaluate various risk factors on outcome as 
well as to assess the performance of prognostic models in Southeast Asia.   
2.1 Study 1 – Incidence and outcome of male breast cancer: an international 
population-based study (Chapter 5)   
Increasing incidence rate and improved survival of female breast cancer have been 
reported in many studies.  Due to the low incidence, good recent data on risk and 
outcome of male breast cancer is lacking and most studies suffered from small 
sample sizes, short follow-up and non–population-based designs. This study aims 
to improve our understanding of risk and outcome of male breast cancer in relation 
to female breast cancer, to: 
i) Compare the period trend in incidence between both genders  
ii) Compare the period trend in survival between both genders  
iii) Compare the relative survival between both genders  
2.2. Study 2 – The impact of in situ breast cancer and family history on risk of 
subsequent breast cancer events and mortality: a population-based study from 
Sweden (Chapter 6)  
There is lack of evidence on long term outcome of breast carcinoma in situ and the 
aims of this study are to: 
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i) Assess the risk of subsequent invasive breast cancer and mortality in 
women diagnosed with in situ breast cancer  
ii) Assess the change of risk of subsequent invasive breast cancer over 
time which might be attributed to advancement in detection and 
treatment.   
iii) Evaluate the effect of family history, age at diagnosis, follow-up time 
on risk of subsequent invasive breast cancer and mortality after 
diagnosis of breast carcinoma in situ  
 
2.3 Study 3 – Validation of the CancerMath prognostic tool for breast cancer in 
Southeast Asia (Chapter 7)  
The most commonly used prognostic prediction programme Adjuvant! Online 
overestimates survival in Asian patients. We aim to validate another prognostic 
model CancerMath for early breast cancer patients in Southeast Asia.  
 
2.4 Study 4 – Predicting survival of de novo metastatic breast cancer in Asian 
women: systematic review and validation study of prognostic tools. (Chapter 8)  
In Asia, up to 25% of breast cancer patients present with distant metastases at 
diagnosis. Given the heterogeneous survival probabilities of de novo metastatic 
breast cancer, individual outcome prediction is challenging. The aim of the study is 
to identify existing prognostic models for patients with de novo metastatic breast 
cancer and validate them in Asia.   
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Chapter 3 Source of data and study design  
 
In epidemiological studies, it is important to define the study population and study 
design in advance as it will directly affect the validity and generalizability of the 
findings.  In this chapter, we discuss the study design and source of data in detail.      
3.1 Overview of epidemiological study designs 
 
Epidemiological studies can be either experimental or observational, depending on 
whether the researchers assign exposure to the study subjects or simply observe the 
effect of exposure. For etiological research, the aim is to investigate a causal 
relation between a risk factor and a health-related event.  Confounding is a central 
issue when establishing causality because the true association can be distorted by 
another variable. One method to control for confounding is through random 
allocation of exposure in an experimental study so that the comparison groups are 
as similar as possible. Such study design is known as randomized controlled trial 
(RCT).  RCTs and pooled analysis of RCTs provide the highest quality of evidence 
as it eliminates both known and unknown confounding bias [221].  However in this 
thesis, RCT was not feasible in study 1 and 2 as certain risk factors cannot be 
randomly administered to patients, such as gender, time of diagnosis and family 
history.  For prognostic research studies such as study 3 and 4, the aim was to 
predict the outcome in a multivariate manner instead of establishing the causal 
relation.  In this type of studies, confounding is not an issue. RCTs are not 
appropriate for prognostic studies, except for impact studies which aim to measure 
the effect of using a prognostic model on doctors’ behavior, patient outcome, or 
cost effectiveness of care compared with not using such model [222-224].   
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Well-designed observational studies, mainly cohort study and case-control study 
can also provide high level of evidence [221].  For prognostic research where RCT 
is not appropriate, prospective cohort study provide the highest level of evidence 
[225].  In a cohort study, a group of people who are at risk of a specific outcome 
are selected based on their exposure status and followed over a period of time to 
determine outcome.  The cohort can be followed prospectively for events to happen 
or the experience of a cohort over a period of time can be reconstructed 
retrospectively using historical records when outcome has already occurred.  In 
both prospective and retrospective cohorts, exposure status is determined before the 
occurrence of outcome.  Therefore a temporal relationship can be potentially 
established to demonstrate causal association.  Prospective data collection can be 
very time consuming and costly to have sufficient number of events. In 
retrospective studies, information on exposure and potential confounders in existing 
records might be incomplete and inaccurate[226].   Other disadvantages of cohort 
studies include loss of follow-up and differential misclassification of outcome 
between exposed and non-exposed groups.  For example, women who take oral 
contraceptives are monitored and examined more carefully for conditions like 
hypertension and venous thrombosis thus have higher probability of detection than 
non-users [227, 228].  
Another common observational study design is case-control study, in which the 
frequency of exposure is compared between individuals with (cases) and without 
(controls) a particular outcome. To minimize selection bias, the cases and controls 
should come from the same source population.  Cases and controls can be matched 
based on certain variables to account for confounders.  In contrast to cohort study, 
the outcome status is already known and exposure status is determined after 
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occurrence of outcome, which can introduce recall bias as cases are more likely to 
report exposure[226].  Although case-control study does not allow estimation of 
incidence and is more susceptible to recall bias and interview bias, it is quick, 
inexpensive and more efficient for rare outcomes [229].   The last common study 
design of observational study is cross sectional study, which is conducted at one 
time point to usually estimate the prevalence of certain outcome[230].  Therefore it 
cannot assess the causal effect and cannot be used for outcome and prognostic 
research.  
In this thesis, all four studies are retrospective cohort studies by using existing 
population-based or hospital-based database.                                                                                              
3.2 Consolidation of population-based cancer registry data – Study 1 
Six population-based cancer registries in Denmark, Finland, Geneva (Switzerland), 
Norway, Singapore, and Sweden contributed incident cases to the study on male 
breast cancer.  
The Danish Cancer Registry 
The Danish Cancer Registry was founded in May 1942 and started registering all 
incidences of malignant neoplasms and certain benign lesions from Danish 
residents in the following year [231].  Reporting to the cancer registry has become 
mandatory since 1987.  For unknown cancers not notified by hospital departments, 
pathology departments or physicians in general practice and only identified in death 
certificates, detailed information can be obtained from the national death certificate 
system [232].  Such cases have reduced from 19% in the 1940s to 1-2% in the 1980s.  
The completeness and validity of the registry was assessed to be 95% to 98% in 
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1977 [233].  The proportion of morphologically verified cases was 89% [231].  
TNM stage information is available only after 2004, and the completeness of TNM 
registration for breast cancer was 85.4% [234]. Information on emigration, 
immigration and death was updated once a year by linkage with the Danish Civil 
Registration System and the Danish Register of Causes of Death using the ten-digit 
unique Civil Personal Register number (personal identity number) allocated for 
each resident at birth or when obtaining permanent residence [231].  
The Finnish Cancer Registry  
The Finnish Cancer Registry was founded in 1952 and all hospitals, physicians and 
pathological and haematological laboratories must send a notification of every 
cancer case from 1961 onwards [233]. The completeness of registration of solid 
tumors was reported to be over 99% [235].  In 2003-2007, 93% of cancer cases 
were register based on microscopic verification and 2% were based only on death 
certificates [236].  Data on stage and basic treatment has been recorded since the 
beginning of cancer registration. Vital status, date and causes of death are annually 
matched with the record from Cause of Death Register and Central Population 
Register.  
The Geneva Cancer Registry  
The registration of cancer in Switzerland is managed by cantonal level registers 
[237]. The Geneva Cancer Registry records all incident cancers occurring in the 
population of the canton of Geneva since 1970[238].  All hospitals, pathology 
laboratories, and private practitioners are required to notify all cancer cases [238]. 
Completeness of registration was reported to be very high with less than 2% of 
cases were recorded from death certificates only [239].  Information on stage at 
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diagnosis, hormone receptor status and treatment within 6 months after diagnosis is 
included in the registry [238]. Cause of death is obtained from death certificate or 
hospital records as well as annual active follow-up via linkage with Cantonal 
Population Office [240].  
The Norwegian Cancer Registry 
The Cancer Registry of Norway has collected cancer notifications since 1952.  All 
hospitals, laboratories and general practitioners are legally obligated to report new 
precancerous and cancerous cases within two months of diagnosis [241, 242].  
Estimated completeness of the registry was 98.8% for the period of 2001 to 2005 
and 93.8% of cases were morphologically verified [242].  The incidence registry 
includes basic data collected from clinical and pathological reports, patients’ 
discharge and mortality records [241].  Clinical registries with detailed information 
on diagnosis, pathological examination, treatment and follow up were also 
established for several major types of cancer [241]. Death records come from 
National Population Registry and are compared with data from the Cause of Death 
Register run by Statistics Norway at least once a year. 
The Singapore Cancer Registry  
The Singapore Cancer Registry started registration of incident cancers in January 
1968 and notification became compulsory in 2009[174].  Multiple sources of 
notifications such as medical profession, pathological reports, discharge records 
and death certificates are used to ensure the registry is as complete as possible. The 
proportion of cases by death certificate only was 4.2% between 1968 and 1997, 1.0% 
for the period 1993-1997 and 0.9% for the period 1998-2002 [243, 244].  Vital 
status and cause of death is retrieved through linkage to the death registry and nearly 
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all deaths are certified in Singapore [174]. Information on stage is available from 
2003 onwards, whereas no information on treatment is available. 
The Swedish Cancer Registry  
The Swedish Cancer Registry has registered newly detected cancer cases since 1958 
and registration, coding and quality check has been performed at six regional 
registries since the mid-1980s[245]. It is compulsory for all healthcare providers to 
notify new cancer case and approximately 99% of the cases are morphologically 
verified. Less than 2% of cases were not reported in the late 1970s and recent study 
showed underreporting of 3.7% of cases in 1998 based on records from Hospital 
Discharge Register [245, 246].  Cases reported by death certificates only are not 
included in the registry[233]. Vital status and date of death and migration is 
obtained via linkages to the Cause of Death Register and the Total Population 
Register. Stage has been collected since 2004 but was not included in our analysis.  
There is no information on treatment. 
3.3 Linkage of multiple population-based registries in Sweden – Study 2 
The Multi-Generation Register (MGR) in Sweden includes more than 10 million 
Swedish residents who are born after 1932 in Sweden and have ever been registered 
in Sweden after 1st January 1961[247]. These people are called index persons. Basic 
information on index person such as date of birth and country of birth and on their 
parents is taken from three registers in Sweden, i.e. the Total Population Register, 
Personal Records and Statistics Sweden’s register of births. The coverage is 
comprehensive for index person except for missing data on those emigrated 
between 1961 and 1967 and never returned.  Information on both biological and 
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adoptive parents of index persons is recorded and 98% maternal information and 
95% paternal information is complete for the Sweden-born subpopulation [247, 
248].  This register is updated in March every year and enables identification of 
parents, siblings, children and other relatives of the index person.  Via the unique 
national registration number given at birth or immigration, information of index 
person and his/her relatives can be retrieved from other registers at Statistics 
Sweden or other authorities in Sweden.  
The Swedish Cancer Registry recorded DCIS as invasive cancer until 1980 and 
since then both DCIS and LCIS were classified as in situ [249].  The register does 
not distinguish ductal from lobular in situ breast cancer before 1990 and has no 
information regarding tumor stage or treatment.  The completeness of registration 
of in situ cases improved from 78% in the 1980s to 95% in early 1990s and the 
correctness improved from 94% to 96% [250].  For the second study, we linked the 
data from the MGR with the Swedish Cancer Registry using the unique national 
registration number and identified women in MGR diagnosed with breast 
carcinoma in situ to be included in the analysis.    
3.4 The Singapore Malaysia Hospital Based Breast Cancer Registry – Study 3 and 
Study 4  
Singapore Malaysia Hospital Based Breast Cancer Registry consists of three 
hospital-based breast cancer registries in Singapore and Malaysia. National 
University Hospital (NUH) and Tan Tock Seng Hospital (TTSH) are two public 
tertiary hospitals in Singapore. The breast cancer registry at National University 
Hospital (NUH) in Singapore contributed cases diagnosed since 1990 whereas the 
Tan Tock Seng Hospital (TTSH) registry included patients diagnosed from 2001 
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onwards. University Malaya Medical Centre (UMMC), located in Kuala Lumpur, 
Malaysia, has prospectively collected data on breast cancer cases since 1993.  These 
registries have received approval from respective ethical review committees. All 
three registries include data on basic patient demography, age and date of diagnosis, 
histologically determined tumor size, number of positive lymph nodes, ER and PR 
status (positive defined as 1% or more positively stained tumor cells at NUH or 10% 
or more positively stained tumor cells at UMMC and TTSH, negative, or unknown), 
HER2 status based on FISH and IHC if FISH is not performed  (positive defined as 
FISH positive or IHC score of 3+, negative defined as FISH negative or IHC scored 
of 0 or 1+, equivocal defined as IHC score of 2+, or unknown), histological type 
(ductal, lobular, mucinous, others, or unknown), grade (1, 2, 3, or unknown), type 
of surgery (no surgery, mastectomy, breast conserving surgery, or unknown), 
chemotherapy (yes, no or unknown), hormone therapy (yes, no, or unknown), and 
radiotherapy (yes, no, or unknown). Stage I to IV was categorized according to the 
sixth edition of AJCC staging system.  De novo metastasis was defined as distant 
metastasis detected within three months after diagnosis and metastasis in the 
ipsilateral supraclavicular lymph nodes only was not considered as metastatic 
patients according to the sixth edition.  Site(s) of metastasis (bone, lung, liver, brain, 
soft tissue or other organ) was recorded for de novo metastatic breast cancer patients 
at all three registries.  Detailed chemotherapeutic treatment regimens were only 
available for UMMC patients. For chemotherapy, cyclophosphamide methotrexate 
fluorouracil (CMF) was categorized as first generation regimen and fluorouracil, 
epirubicin and cyclophosphamide (FEC), and doxorubicin and cyclophosphamide 
(AC) followed by paclitaxel were second generation. Docetaxel, doxorubicin and 
cyclophosphamide (TAC), and FEC followed by doxorubicin were categorized as 
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third generation. Hormone therapy was categorized into five groups: tamoxifen, 
aromatase inhibitors (AI), tamoxifen followed by AI, ovarian ablation, and ovarian 
ablation plus tamoxifen. Death information was obtained from the hospitals' 
medical records and ascertained by linkage to death registries in both countries. 
For study 3, Women diagnosed with pathological stage I to III breast cancer 
between 1990 and 2011 were identified from the registry.  For study 4, de novo 
metastatic breast cancer patients diagnosed between 2000 and 2010 were identified 
from this registry.  
3.5 Systematic review – Study 4 
Systematic review is a strategy to gather best available evidence on a specific 
research question and the results from each study on this topic can be pooled and 
analyzed by an explicit method known as meta-analysis (not performed in this 
thesis).  In the fourth study in this thesis, a systematic review on prognostic tools to 
predict overall survival of metastatic breast cancer patients was conducted.   
Before initiation of a systematic search of relevant studies, the research question 
must be clearly structured, defining the study population, outcome of interest, 
exposure/intervention, and study design without ambiguity [251].  To ensure the 
quality of systematic review, PRISMA (Preferred Reporting Items for Systematic 
reviews and Meta-Analyses) guidelines were developed by an international group 
of multidisciplinary experts [252]. Inclusion and exclusion of studies should follow 
the study selection criteria specified earlier and reasons for exclusion should be 
recorded.  Evidence from selected studies can be summarized qualitatively and 
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quantitatively (not done in this thesis).  It is also important to assess the quality of 
the studies as it may potentially affect the interpretation of the results.  
Recently a more specific checklist for systematic reviews of prediction modelling 
studies was designed to guide formulation of research question and appraisal of 
prediction modelling studies [253].  The type of prediction modelling studies for 
which this checklist can be applied to includes development with or without 
external validation and external validation studies with or without modification of 
the original model.  This checklist can be used for both diagnostic and prognostic 
prediction model and it covers 11 domains, including source of data, participants, 
outcomes, candidate predictors, sample size, missing data, model development, 
performance, evaluation, results, and discussion.  The systematic review conducted 
in the fourth study has extracted relevant items listed in each domain from studies 





Chapter 4 Statistical analysis  
 
This chapter gives a brief introduction of the statistical techniques used and 
discussed in this thesis.  The detailed analytical plan for each study can be found in 
Chapter 5-8.  
4.1 Survival analysis  
 
To study the outcome of breast cancer, we have to follow the patient from diagnosis 
of breast cancer to occurrence of a particular event, such as death or recurrence of 
cancer.  The duration from time of diagnosis to the event is called the “time-to-
event” or “survival time”.   In some circumstances such as the event of interest has 
not occurred when the study ends or when the patient dies, or event status is not 
known due to lost-to-follow-up, the survival time is right censored.  We then use 
the observed survival time to draw implication about the true survival time [254].   
In most studies, we are interested to know the probability of survival after breast 
cancer diagnosis.  The simplest way is to present the proportion of subjects whose 
survival time exceeds a fix period of time (e.g. 5-year).  However it does not take 
observations that are censored during the first 5 years into consideration and does 
not fully utilize the exact survival time.  Two methods were developed to deal with 
censoring data: life table method and Kaplan-Meier method.  Both methods assume 






Life table (actuarial) method 
The proportion of dying (qi) and proportion of survival (pi) are calculated for each 
fixed time interval such as every one year after diagnosed by qi= number of patients 
dying during that time interval/effective number exposed to risk of dying and pi=1-
qi  [255].  The effective number at risk of dying (ri) takes both number of patients 
alive at beginning of that interval (li) and number of patients last seen alive 
(censored) during that interval (wi) in to account by assuming censored patients on 
average were followed up for half of the interval, which results in ri=li-wi/2.   The 
cumulative survival rate until end of nth interval is then the product of pi from 1st to 
nth interval.    
Kaplan-Meier method  
The Kaplan-Meier method to estimate survival probability is very similar to the life 
table approach. The only difference is that the probability can be calculated 
whenever a death occurs instead of at the end of a fixed time interval.  As a result, 
the interval length is no longer consistent as comparing to the life table approach.  
The conditional probability of surviving the time interval (can be measured in days, 
months or years depends on how precise the data is) given being alive at beginning 
of the interval is calculated as number of patients survived by the end of internal 
divided by number of patients alive at beginning of that interval. Censored cases 
are considered to have survived throughout the time interval. The surviving 
probability up to certain time point is then the product of conditional probabilities 
of previous intervals (product limit method).  Standard error of the estimates can be 




The Kaplan-Meier survival curve can be plotted based on estimate at end of each 
interval. The survival curve starts at value of 1 (or 100%) and proceeds horizontally 
until an event occurs.  The depth of drop depends on how many events occur at that 
point of time. Two or more Kaplan-Meier survival curves of different subgroups 
such as patients with and without treatment can be compared using log-rank test, 
which is a chi-square test with degree of freedom equals to number of groups-1.  
The null hypothesis is that there is no difference between the groups at any time 
point.  At each time (j) an event occurs, observed (Oij) and expected (Eij) number 
of events are calculated for each group i. The test statistics can be approximated by 
∑ሺ୓୧ି୉୧ሻమ୉୧   where and Oi=∑Oij and Ei=∑Eij.   
Relative survival  
Overall survival estimates the probability surviving all causes of death.  Sometimes 
we are only interested in net probability of survival with cancer as the only cause 
of death.  Net survival (or excess mortality) can be estimated by cause-specific 
survival where death from other causes other than cancer of interest is censored. 
However cause of death is difficult to determine when metastasis or treatment 
complication occurs and death certificates are often unreliable or unavailable for 
population-based study [256].  Relative survival is used as another measure of net 
survival by calculating the ratio of observed survival of cancer patients to the 
expected survival of a comparable cohort from the general population, usually 
matched by gender, age and calendar period [257]. Observed survival of the cancer 
patients is estimated using the life table approach and expected survival can be 
derived from annual probability of death reported in  population life tables 
(stratified by gender- and calendar period) according to Ederer I [257],  Ederer II 
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[258] or Hakulinen method [259].   Population life table or annual probability of 
death is usually published and publically available as part of national statistics in 
many countries.  They can also be downloaded from the Human Life-table Database 
(http://www.lifetable.de/) and the Human Mortality Database 
(http://www.mortality.org/). The expected survival estimated from these three 
methods does not differ much except for long term survival of cancer sites which 
affect people from wide range of age groups. Ederer II method is preferred in many 
cancer registries as the relative survival calculated is lower than the other two 
methods.     
Standardized incidence/mortality ratio 
Occurrence of cancer relapse or death in a particular population can be compared 
with a reference population using standardized incidence/mortality ratio (SIR and 
SMR).   The ratio is calculated as observed number of events (recurrence if SIR or 
death if SMR) divided by the expected number of events, where expected number 
is incidence/mortality rate of the reference population multiplied by the person-time 
of the population of interest.  Expected number can be estimated for each gender-, 
age-, period-specific group and then added up therefore the ratio is standardized to 
adjust for different age distributions of the two populations.  An SIR/SMR of 1 
indicates no difference of incidence/mortality between the two populations.  
Confidence interval (CI) is calculated for SIR/SMR by assuming observed number 
of events is Poisson distributed to determine whether the difference is significant 




4.2 Regression analysis  
 
The relationship between one dependent (response) variable and a group of 
independent (explanatory) variables can be modelled statistically using regression 
analysis.  The simplest regression model is linear regression, where the relationship 
between dependent variable Y and independent variables Xi is assumed to be linear, 
and can expressed as Y=β0 + β1X1 + β2X2+ …+βnXn +ε.  The coefficient βi shows 
how much Y will change when Xi increase by 1 unit.   
In epidemiological studies, the effect size of risk factor on outcome can be estimated 
using regression model while adjusting for other confounders.  In prognostic 
research, several predictors can be combined mathematically using regression 
model to predict outcome.  In this section, we will discuss several regression 
methods used and/or discussed in this thesis.   
Cox proportional hazard regression model  
In previous section, we have demonstrated survival time of two or more groups can 
be compared using Kaplan-Meier curves and log-rank test.  However this analysis 
is univariate and is only suitable for categorical variables. Cox regression is 
developed to study the joint effect of multiple covariates and to estimate the effect 
of one risk factor while adjusting for confounders.  The dependent variable Y in a 
Cox regression model is the hazard function at a given time t, denoted λ(t),  which 
can be considered as the instantaneous rate that an event occurs at time t [262, 263].   
It can be related to various explanatory variables as λ(t) = λ0(t)exp(β1X1 + …+βnXn) , 
and λ0(t) is the baseline hazard function when all the explanatory variables are zero.  
The ratio of two hazard functions is known as hazard ratio and is assumed to be 
constant over time, i.e. the hazard of one group is proportional to the other group 
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over time. This assumption can be tested using complementary log-log plot.  
Estimates of βi and CI can be obtained by method of partial likelihood.  The hazard 
ratio comparing Xi=xi to Xi=xi’ is then exp(βi(xi- xi’)).  The hypothesis of equal 
hazard，i.e. exp(βi)=1, or  βi =0,  can be tested using partial likelihood ratio test.  
In prognostic research, weighted sum of the covariates in the Cox model, where the 
weights are the coefficients βis, is always used as prognostic index/score [264].  
Poisson regression  
Although Cox regression is widely used in survival analysis, it does not 
accommodate multiple time scales simultaneously (e.g. attained age, time since 
diagnosis, and calendar time) and cannot be applied to model a difference in two 
rates [265, 266].  Poisson regression is used as an alternative method.  It is called 
Poisson regression because number of events occurred (Y) is modelled by 
generalized linear model with log link function under the assumption of Poisson 
distribution.  The logarithm of expected value of Y, denoted log(µ) can be modelled 
as log(µ) = β0 + β1X1 + …+βnXn.  The dependent variable can also be 
incidence/mortality rate Y/t (t is the accumulated person-time at risk) and the 
equation becomes log(µ/t) = β0 + β1X1 + …+βnXn, .  It can be further modified as 
log(µ)= log(t)+ β0 + β1X1 +…+βnXn,  where log(t) is known as the offset.  Based on 
the model, we can calculate exp(βi(xi- xi’)) as the incidence/mortality rate ratio 
comparing Xi=xi to Xi=xi’. All the covariates has multiplicative effect on 





Relative excess risk  
As discussed earlier, relative survival is a measure of net survival (or excess 
mortality) attributable to cancer.  To evaluate effect of one risk factor on relative 
survival while controlling for other confounders, the excess mortality (observed 
mortality minus expected mortality) can be modelled under the assumption of 
Poisson distribution as a multiplicative function of covariates and offset by 
logarithm of person-time at risk, log(µ − d∗) = ln(t) + β1X1 +…+βnXnm, where d∗ 
is expected number of death.   The ratio of excess mortality comparing Xi=xi to 
Xi=xi’ (relative excess risk, RER) is then exp(βi(xi- xi’)), which  is the same as rate 
ratio in Poisson regression.   
Additive Poisson model and excess additive risk  
In both Cox regression and previous examples of Poisson regression, effects of 
different factors on risk are combined multiplicatively, i.e. risk ratio of having 
multiple risk factors is a production of individual risk ratio for each risk factor.  In 
some situation, an additive effect, where the risk differences from different factors 
are added together, is more appropriate.  For count data with person time, rate can 
be modelled using identify link instead of natural log link, i.e. µ/t = β0 + β1X1 + 
β2X2+ …+βnXn.   
Using this method, the absolute difference of observed and expected mortality rate, 
known as excess additive risk (EAR) can be estimated using a Poisson additive 
model with expected number of cases as the offset.  A likelihood ratio test was used 




4.3 Validation of prognostic model  
 
The third and fourth studies in this thesis validated various prognostic models 
developed for breast cancer patients. The predicted outcome from these prognostic 
models is usually an absolute risk of an event or a prognostic score [267].   Most of 
prognostic models are developed using a limited sample size and having many 
potential predictors being tested.  The resulting model may be over-fitted to the 
derivation data and shows optimistic performance when it is applied to data from 
the same source as the development set [268, 269].  Although internal validation 
using split-sample, cross validation or bootstrapping can correct the optimism of 
model performance [270], it is limited in terms of assessing generalizability of the 
model [269].   Therefore it is important to validate prognostic models in an external 
dataset, either from different time period or different geographical area.  The 
predictive performance of the prognostic model can be evaluated in terms of its 
discrimination and calibration.  
Discrimination   
Discriminative ability of a prognostic model describes how well the model 
distinguishes between patients with good and poor outcome.  If the outcome of 
interest is dichotomous (with or without event of interest), different cut-off levels 
can be applied to the prognostic score/predicted probability to classify a patient as 
positive or negative for outcome.  For each possible threshold, sensitivity and 
specificity can be calculated.  Each pair of sensitivity and 1-specificity can be 
plotted against each other and the resulting curve is known as the receiver operating 
characteristic (ROC) curve.  The area under a ROC curve (AUC) is interpreted as 
the probability of assigning a higher prognostic score or predicted risk to a 
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randomly selected individual with the outcome of interest than to another randomly 
selected individual without the outcome. For survival models, length of follow up 
should be specified  so that dichotomous survival status can be used for ROC 
analysis [271].  However censored cases cannot be included in analysis due to their 
unknown status. Another adapted method was developed by Harrel to compare the 
survival time between any possible random pair of subjects [272].   The probability 
of assigning greater prognostic score to a person who survived longer is called 
concordance statistic (C-statistic).  Same as AUC, a C-statistic of 0.5 indicates no 
discrimination and value of 1.0 means perfect discrimination. 
Discrimination can be affected by the heterogeneity of the validation population. 
As the spread of the predicted probability or score increases in the validation set, 
the model tends to discriminate better [273]. Therefore the difference in underlying 
risk distribution between development and validation sets could affect its 
discrimination in the validation study.   
Calibration  
Calibration refers to the agreement between the predicted outcome and observed 
outcome, which reflects the accuracy of the prediction. It can be assessed by 
splitting the data into several groups, normally based on deciles of predicted 
outcome, and then comparing the predicted outcome and observed outcome in each 
decile. For example, for binary outcome, the proportion of events can be compared 
with average or median predicted probability for each group. A calibration plot is 
presented by plotting the observed outcome against predicted outcome for each 
group.  The 45 degree diagonal line illustrates perfect agreement between predicted 
and observed outcome.  The observed number of events can also be compared with 
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predicted number of events in each group (sum of predicted probability) using 
Hosmer–Lemeshow test. In contrast to discrimination, calibration is affected by the 
differences in means of predicted outcome between development and validation 
sets [273].  If persistent under-prediction or over-prediction is observed across all 
groups, it is necessary to recalibrate the model.   
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Chapter 5 Incidence and outcome of male breast cancer: an 
international population-based study 
Originally published by the American Society of Clinical Oncology. [Miao H, 
Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Larønningen S, Mellemkjær 
L, Czene K, Hartman M:  Journal of Clinical Oncology 29 (33), 2011 Nov 20: 4381-
6] 
 
5.1 Motivation  
 
Male breast cancer is a rare disease, accounts for 0.5% to 1% of all breast cancer 
cases [11, 274-276]. Similar to female breast cancer, the risk of male breast cancer 
increases steadily with age [11, 277], although men are, on average diagnosed at 
later ages and do not display the typical deceleration in risk after the age of 50 years 
as seen in women, described by Clemmesen over 60 years ago [11, 13, 274, 277-
279].  
Male breast cancer is reportedly associated with worse outcome as compared to 
female breast cancer [126, 276]. Some studies have suggested that survival 
differences between genders disappear after stratification for age and stage [126, 
278, 280]. However, given the low incidence of male breast cancer, many of these 
studies suffered from small sample sizes, short follow-up time and a non-
population-based design, limiting their interpretability.  
Over the last few decades, survival of female breast cancer has improved 
substantially. This is likely a combined result of earlier detection and improvements 
in treatment [7, 281]. Given the scarcity of male breast cancer, solid recent data on 
risk and outcome for male disease is lacking. We have undertaken a population-
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based international study, with the aim to improve our understanding of risk and 
outcome of male breast cancer in relation to female breast cancer.  
5.2 Methods 
 
For the current study, we included patients with invasive breast cancer from all six 
participating regions diagnosed between 1970 and 2007 with the exception of 
Denmark, where patients diagnosed up to 2006 were included. Detailed description 
of cancer registries in these six regions can be found in Chapter 3.  All datasets 
contained information on sex, date of birth, date of diagnosis, duration of follow-
up, vital status, date of death and date of migration for all individuals. Stage at 
diagnosis was available for patients diagnosed in Finland (localized, regional, 
distant, or unknown). For patients from Geneva, Norway and Singapore, TNM 
stage was transformed to localized, regional, or distant, with stage I as localized, 
stage II and III as regional, and stage IV as distant. Basic treatment information was 
available for Finland, Geneva and Norway and included surgery (yes, no, or 
unknown), chemotherapy (yes, no, or unknown), radiotherapy (yes, no, or unknown) 
and hormonal therapy (yes, no, or unknown). 
Patients with an invasive cancer diagnosis before first breast cancer were excluded, 
as were individuals who immigrated from another region before diagnosis, because 
of the possibility of misclassification of cancer history. For individuals with 
multiple breast cancer diagnoses, only the first cancer was included in analysis. Our 
final study population comprised 459,846 women and 2,665 men diagnosed with 
invasive breast cancer. Follow-up started at time of diagnosis, and survival time 
was defined as the time between the date of diagnosis and date of death, emigration, 




Mann-Whitney U test and Chi-square test were performed to test gender differences 
in distribution of age, stage and treatment. Significance level of the associations 
was based on valid proportions only (ie, after excluding missing information). The 
age standardized incidence rate of invasive breast cancer was calculated using the 
total female and male population of the six regions as denominators and was 
directly standardized to world standard population with 5-year age groups.  
Overall survival was evaluated using Kaplan-Meier analysis stratified by gender 
and stage. We applied relative survival analysis to account for differences in life 
expectancy between men and women. Overall relative survival ratios (RSRs) for 
both genders were estimated at 5 and 15 years follow-up. To investigate 
improvements in relative survival over calendar time for men and women, we 
evaluated trends in 5-year RSR by stage and over time (10-year categories).  
To adjust for potential confounders such as age at diagnosis, calendar period of 
diagnosis (grouped by every five years), follow-up time (group by every one year), 
region, stage and treatment, we modelled the excess risk using Poisson regression. 
The reference category for gender comparison was the female group. Regression 
models were built using three datasets: all individuals (i.e., analysis including 
individuals from all regions), individuals from regions with stage information (i.e. 
Finland, Geneva, Norway and Singapore) and individuals from regions with both 
stage and treatment information (i.e. Finland, Geneva and Norway).  On the basis 
of the latter dataset, we stepwise evaluated the effect of adjustment for age, stage, 
and treatment on the relative risk of death from breast cancer for males compared 




5.3 Results  
 
Male breast cancer (n=2,665) represented 0.6% of all breast cancers (Table 5.1), 
and this proportion was similar for all 6 regions. Women were diagnosed with 
breast cancer at a younger median age than men (61.7 vs. 69.6 years, respectively; 
p<0.001). Among the 190,030 (41%) breast cancer patients with information on 
stage, 41% of the men and 44% of women were classified as having localized 
disease. Distant disease extent accounted for 11% and 6% for men and women 
respectively (p<0.001). For 167,169 patients (36%) with information on treatment, 
men were significantly less likely to receive surgery and radiotherapy, but there 
were no differences in the administration of chemotherapy and hormonal therapy.   
Table 5.1 Characteristics of female and male breast cancer cases diagnosed in 









Region   <.001* 
Denmark 677 (25.4%) 97,228 (21.1%)  
Finland 347 (13.0%) 86,083 (18.7%)  
Geneva 61 (2.3%) 9,980 (2.2%)  
Norway 435 (16.3%) 70,263 (15.3%)  
Singapore 74 (2.8%) 22,787 (5.0%)  
Sweden 1,071 (40.2%) 173,505 (37.7%)  
Age, years    
Median age 69.6 61.7 <.001¶ 
0-40 62 (2.3%) 25,154 (5.5%) <.001* 
40-60 612 (23.0%) 185,901 (40.4%)  
60+ 1,991 (74.7%) 248,791 (54.1%)  
Calendar Period   <.001* 
1970-1977 490 (18.4%) 67,478 (14.7%)  
1978-1987 607 (22.8%) 101,755 (22.1%)  
1988-1997 728 (27.3%) 130,029 (28.3%)  
1998-2007 840 (31.5%) 160,584 (35.0%)  
Stage   <.001† 
Localized 379 (41.3%) 83,828 (44.3%)  
Regional 311 (33.9%) 64,945 (34.3%)  
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Distant 100 (10.9%) 10,561 (5.6%)  
Unknown 127 (13.9%) 29,779 (15.8%)  
Total 917 189,113  
Treatment    
Surgery   <.001‡ 
Yes 728 (86.4%) 150,769 (90.7%)  
No 79 (9.4%) 9,572 (5.8%)  
Unknown 36 (4.3%) 5,985 (3.6%)  
Radiotherapy   <.001‡ 
Yes 251 (29.8%) 63,751 (38.3%)  
No 447 (53.0%) 81,775 (49.2%)  
Unknown 145 (17.2%) 20,800 (12.5%)  
Chemotherapy   0.06‡ 
Yes 127 (15.1%) 31,125 (18.7%)  
No 542 (64.3%) 110,749 (66.6%)  
Unknown 174 (20.6%) 24,452 (14.7%)  
Hormonal therapy   0.09‡ 
Yes 190 (22.5%) 35,400 (21.3%)  
No 508 (60.3%) 109,199 (65.7%)  
Unknown 145 (17.2%) 21,727 (13.1%)  
Total 843 (100%) 166,326 (100%)  
      †† Denmark contributed case diagnosed between 1970 and 2006   * Chi-square 
test  ¶ Mann-Whitney U test † Chi-square test on valid proportion only, using subset 
with stage information (Finland, Geneva, Norway and Singapore) ‡ Chi-square test 
on valid proportion only, using subset with treatment information (Finland, Geneva 
and Norway)  
 
The overall age standardized incidence rates were 0.4 per 100,000 person-years in 
men and 66.7 per 100,000 person-years in women. The incidence of breast cancer 
in women increased by more than 50%, from 51.4 per 100,000 person-years in the 
early 1970s to 80.3 per 100,000 person-years after the year 2000 (Figure 5.1). The 
overall incidence of disease in men remained stable at approximately 0.4 per 
100,000 person-years all the time (Figure 5.1). Compared with the European 
countries, Singapore had a lower incidence rate for both genders, but a faster 
increase in incidence, which tripled in women and quadrupled in men from the early 
1970s to the 2000s (female: 23.97 to 63.17 per 100,000 person-years; male: 0.05 to 
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0.21 per 100,000 person years) (Figure 5.2 and 5.3). The increased incidence for 
men in Singapore was not statistically significant. Men had a worse overall survival 
compared with women (Figure 5.4), except for patients with distant spread of 
disease, for whom overall survival was similar for both genders. Disease-specific 
survival (as estimated by relative survival) was significantly worse for male patients 
at both 5 and 15 years compared with female patients (5-year RSR,  0.72 vs 0.78 
respectively; 15-year RSR 0.50 vs. 0.61 respectively) (Table  5.2). This corresponds 
to a 27% higher unadjusted 5-year excess mortality risk for men compared with 
women (RER=1.27, 95% CI, 1.13-1.42; Table 5.2, model 1a) and a 36% higher 15-
year excess risk (RER=1.36, 95% CI, 1.24-1.50; Table 5.2, model 1a). After 
adjusting for region, age and year of diagnosis, follow-up time, and stage, there was 
no significant difference in 5-year and 15-year excess mortality between men and 
women (Table 5.2, model 3a and 3b). Additional adjustment for treatment further 
reduced the RER to 0.78 (95% CI, 0.62-0.97; Table 5.2, model 4). A similar pattern 
was observed when assessing 15-year follow-up. For female patients with breast 
cancer, 5-year relative survival increased from 0.66 (95% CI, 0.66-0.67) in 1970 to 
1977 to 0.87 (95% CI, 0.86-0.87) in 1998 to 2007 (Table 5.3). Men experienced an 
improvement in relative survival as well, from 0.67 (95% CI, 0.60-0.72) in 1970 to 
1977 to 0.78 (95% CI, 0.73-0.83) in 1998 to 2007. 
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Figure 5.1 Incidence rate (IR) of male and female invasive breast cancer (standardized to world population), by period of diagnosis (right y-axis 












































































































































Figure 5.4 Kaplan-Meier curve for overall survival of breast cancer patients, by 





 Female  
TIME (years) 0 5 10 15 
Localized 83457 54831 32616 18394 
Regional 64522 31700 15572 7770 























0.0 2.5 5.0 7.5 10.0 12.5 15.0
STRATA: stage=distant gender=Female stage=distant gender=Male stage=local gender=Female
stage=local gender=Male stage=regional gender=Female stage=regional gender=Male
TIME (years) 0 5 10 15 
Localized 374 218 127 57 
Regional 311 136 50 23 
Distant 100 12 4 1 
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RSR, Model 1a and 1b: Crude 
Model 2a and 2b: Adjust for region, time since diagnosis,  age and year of diagnosis 
Model 3a and 3b: Adjust for region, time since diagnosis, age and year of diagnosis and stage 
Model 4: Adjust for region, time since diagnosis, age and year of diagnosis, stage and treatment (surgery, 
chemotherapy, radiotherapy and hormonal therapy) 
RSR, Model 1a and 2a: Entire dataset, N=462,511 
Model 3a: Subset with information on stage (Finland, Geneva, Norway and Singapore), N=190,030  
Model 1b, 2b,3b and 4 Subset with information on treatment (Finland, Geneva and Norway), N=167,169  
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Table 5.3 Breast cancer 5-year relative survival ratio, by gender, calendar period 
and stage 
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5.4 Discussion  
 
With this international population-based study, we show that over the last 38 years, 
male breast cancer incidence has remained at a stable low rate, whereas female 
breast cancer has become increasingly common. In a crude comparison survival is 
worse among men than among women. The poorer observed survival of male 
patients is largely explained by their more advanced stage at diagnosis, their higher 
age at diagnosis, and lower proportion being treated with locoregional treatment. 
After adjusting for these factors, men actually had better relative survival than 
women.  
Over the last 40 years, the risk of breast cancer in women has continued to increase 
at a steady pace, largely explained by the introduction of mammography screening 
and hormone replacement therapy in the 1980s [43]. Additionally, changes in 
lifestyle and reproductive patterns (i.e. age at menarche, age at first birth, parity, 
and frequency and duration of breast feeding) have influenced female breast cancer 
risks. Virtually all of these factors, except changes in lifestyle, have not affected 
men over time.  
Breast cancer is diagnosed on average 5 to 10 years later in men than in women [11, 
274, 278, 279]. Because of the lack of early detection by mammography and 
awareness of early signs of breast cancer, the duration of symptoms before 
diagnosis has been reported to be longer in men, with a median of 4 to 6 months 
[274, 282]. This may contribute to the differences in stage distribution between men 
and women. In our study, the proportion of distant spread of disease stage was two-
fold in men compared with women.  
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Female breast cancer patients have experienced substantial improvements in 
survival over the last 30 years. The improvement in male breast cancer survival is 
not as pronounced. The survival improvement in women is partly explained by the 
introduction of screening (both opportunistic and within national programmes 
targeted to women only), leading to earlier detection and detection of indolent 
tumors and over-diagnosis. Advances in treatment (in particular, the introduction 
of tamoxifen in the 1980s) and standardization of treatment regimens in 
international guidelines have improved breast cancer survival probabilities [7, 147].  
Lack of evidence-based treatment guidelines and differences in compliance with 
treatment may explain why men experience less survival benefit than women. 
Locoregional and adjuvant treatment of male breast cancer has not yet been 
evaluated in randomized trials, and evidence-based treatment guidelines are lacking. 
As a result, most clinicians base their treatment strategy on guidelines for female 
breast cancer. However, systemic treatment, especially anti-hormonal treatment is 
not as straightforward in men. Anti-estrogen treatments like tamoxifen are not well 
tolerated by men, resulting in lower treamtent compliance [283-285]. In addition, 
National Comprehensive Cancer Network guidelines suggest that administration of 
aromatase inhibitors to men is not effective without simultaneous suppression of 
testicular steroidogenesis [286].  
Although the observed survival of male breast cancer is worse than that of female 
disease, male gender is not an independent risk factor of poor outcome after breast 
cancer. Actually, our results suggest the opposite, that male gender is a favourable 
prognostic factor, as shown by the reduced relative excess risk of death after breast 
cancer, after adjustment for age at diagnosis, stage and treatment. This is in line 
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with other studies [126, 280] that found a similar relative survival for women and 
men with early-stage breast cancer, whereas men with late-stage breast cancer had 
better survival than women. Our stepwise adjustment shows that stage and 
treatment differences between female and male patients explain most of the poorer 
(unadjusted) relative survival of men. These results suggest that much improvement 
in outcome of male breast cancer can be achieved by improving earlier detection 
(through awareness and promotion of breast self-examination) and development of 
treatment guidelines.  
We acknowledge that our study suffers from limitations. An unavoidable limitation 
of a study with a time frame of almost 40 years involves the improvements in 
diagnostic performance and the increased diagnostic intensity in women, which has 
led to an increased uptake of small, often indolent cancers. Other limitations are 
discrepancies in staging system among registries and lack of information on tumor 
characteristics such as grade, hormone receptor status and details on systemic 
treatment.  
Strengths of our study include the large number of male patients, the long 
observation time and the high-quality (population-based) data and the completeness 
of follow-up, which allow for unbiased ascertainment of cancers and deaths. Unlike 
previous studies that compared outcome in male and female breast cancer [276, 
287], we accounted for gender differences in life expectancy by looking at relative 
survival and relative excess risk.  
In conclusion, male breast cancer risk has remained constant over the last 40 years. 
Male patients have later onset and more advanced disease than female patients. 
Overall survival of male breast cancer is worse, however after adjustment of life 
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expectancy, age and year of diagnosis, stage and treatment, male breast cancer 




Chapter 6 The impact of in situ breast cancer and family history 
on risk of subsequent breast cancer events and mortality: a 
population-based study from Sweden 
 
6.1 Motivation  
 
Women with in situ breast cancer have an increased risk of developing in situ or 
invasive breast cancer in the ipsilateral or contralateral breast [169, 288-297].  
Moreover women with in situ breast cancer, even after treatment, are at increased 
risk of subsequent invasive breast cancer compared to women in the general 
population [169, 249, 288, 290-295, 298, 299].  The clinical behavior of in situ 
breast cancer is incompletely understood but it is likely that it represents a mixed 
population of indolent and more aggressive tumors. Several factors have been 
associated with invasive recurrences, including patient characteristics [169, 291, 
294], tumor characteristics [169, 291, 300][4, 5, 15] and treatment [168, 169, 301]. 
The influence of a positive family history on subsequent breast cancer is less well 
studied [302-304]. 
The risk of death from breast cancer in women diagnosed with in situ breast cancer 
is considered to be at most only marginally increased, but remains less well 
characterized and, with few exceptions, studies are often limited by short follow-
up and non-population-based designs [249, 305].  
In this study we evaluated the long-term risk of second breast cancer and death 
among women diagnosed with in situ breast cancer, in relation to family history. 
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6.2 Methods  
We selected 8111 women from Swedish Multi-Generation register (MGR) who 
were diagnosed with breast carcinoma in situ between 1st January 1980 and 1st 
January 2005.  Information on family history, any subsequent invasive breast cancer 
or in situ disease in the contralateral breast after the first diagnosis was retrieved 
from the cancer registry.  Family history was defined as having at least one first-
degree relative diagnosed with invasive breast cancer at any point in time.  
Any invasive cancer following in situ breast cancer was reported as a new event, as 
were new in situ breast cancers in the contralateral breast.  Local relapses were not 
recorded. Ipsilateral in situ breast cancer was excluded due to the increased 
probability of being underreported in women with previous in situ breast cancer.  
Thus, we defined subsequent breast events as ipsilateral or contralateral invasive or 
a contralateral in situ breast cancer. Women with any previous invasive or in situ 
breast cancer were excluded, as were women with invasive breast cancer diagnosed 
concurrently with the first in situ breast cancer.  Because incomplete information 
on laterality and in situ breast cancer registration prior to 1980, we restricted our 
cohort to women with a first in situ breast cancer diagnosed after 1980. Linkage 
with the Cause of Death Register and the Total Population Register provided us 
follow-up information regards to death, immigration and emigration.     
Statistical analysis  
To estimate the risk of a subsequent breast event (ipsilateral or contralateral 
invasive or a contralateral in situ breast cancer), all women were followed from the 
date of their first in situ breast cancer diagnosis and continued until a subsequent 
breast cancer, emigration, death, or end of follow-up, whichever came first. We 
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estimated standardized incidence ratios (SIRs) as a measure of relative risk.  The 
expected number of subsequent breast cancer events was calculated as the product 
of the person-years accumulated by women with in situ breast cancer by the age- 
and calendar period-specific incidence of unilateral in situ /invasive breast cancer 
of the female population in the MGR.  Thus SIRs compare gender, age- and 
calendar-adjusted risk of subsequent breast events of in situ breast cancer patients 
to that of the general population. For all estimates of the contralateral breast, the 
background rate of in situ and invasive breast cancer was divided by two, as only 
one breast was “at risk”.  SIRs of subsequent invasive breast cancer was calculated 
for calendar period of first diagnosis, age and time since first diagnosis and stratified 
by family history of breast cancer.  Poisson trend tests for monotonic trend of SIR 
across calendar period, age and time since first diagnosis was performed [261]. We 
used Poisson regression modeling among women with a first in situ breast cancer 
to estimate the independent effects of age, year of diagnosis and time since 
diagnosis as well as effect of family history on the risk of ipsilateral or contralateral 
invasive or contralateral in situ breast cancer.  Since background rates of breast 
cancer vary considerably by age we also estimated excess additive risks (EARs), as 
the difference of observed numbers of subsequent invasive breast cancer and the 
expected number in the general population in the Swedish MGR, as a measure of 
absolute risk for subsequent invasive cancer. EARs were estimated using a 
univariate Poisson model with an identity link function and the expected number of 
cases as the offset. A likelihood ratio test was used to calculate 95% CIs. The 
cumulative incidence was estimated using life table (actuarial) method. 
The standardized mortality ratio (SMR) was used as a measure of relative mortality. 
The expected number of deaths was calculated from the general population in the 
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MGR.  SMRs were also stratified by family history, age at first in situ breast cancer 
diagnosis and type of subsequent breast event.  For overall SMRs, subjects were 
followed from the date of first in situ breast cancer diagnosis until date of 
emigration, death, or end of follow-up, whichever came first. In contrast, in the 
estimates of death by type of subsequent breast event, follow up was started at the 
diagnosis of that particular event. We calculated 95% CIs assuming a Poisson 
distribution for the observed number of cases. All data preparation and analysis was 
done using the SAS statistical package, version 8.2 or higher (SAS Institute Inc., 




Patient characteristics are listed in Table 6.1. Over a follow-up period of 71,458 
person-years, 825 (10.2%) women developed 886 subsequent breast events (118 
contralateral in situ and 768 ipsilateral or contralateral invasive breast cancers). The 
proportion of subsequent breast events was similar in women with as well as 
without a family history (11.3%, n=97 versus 10.0%, n=728). The average time 







Table 6.1 Summary of all women diagnosed with in situ breast cancer from 1980 to 2004. 
 
  All 
No family 
history Family history 
Total  8111 7252 859 
Mean age at first 
in situ breast cancer (SD)  59.09 (12.1) 59.7 (12.1) 53.9 (10.8) 
 
Mean follow-up time, 
years (SD)  
8.8 (5.9) 8.3 (5.9) 7.7 (5.4) 
Year at diagnosis of first 
 in situ  
 
1980-1984 665 624 41 
1985-1989 1211 1108 103 
1990-1994 2046 1835 211 
1995-1999 1963 1727 236 
2000-2004 2226 1958 268 
Age at diagnosis of first 
 in situ  
 
 







40-44 594 507 87 
45-49 1078 903 175 
50-54 1313 1133 180 
55-59 1133 993 140 
60-64 1021 943 78 
65-69 1058 995 63 
70-74 778 748 30 
75+ 801 761 40 










Contralat in situ1  
        
 
 









Ipsilat invasive 376 334 42 
Contralat invasive 303 262 41 
Total invasive¹ 768 677 91 
Second breast event 
total1,2 886 781 105 
 
Type of second events 
 







(# of women) Ipsilat invasive 370 328 42 
 Contralat invasive 299 258 41 
 Total invasive¹ 725 637 88 
 Second breast event total1,2 825 728 97 
 
1includes the events where laterality is missing. 
²ipsilateral in situ events is not included in the study 
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Risk of subsequent breast cancer/in situ 
Table 6.2 presents the risk of second invasive or in situ breast cancer. The risk of a 
subsequent ipsilateral or contralateral invasive breast cancer was increased more 
than fourfold (SIR=4.55, 95% CI, 4.23- 4.88) among women with in situ breast 
cancer as compared to women in the general population and the risk for a 
contralateral in situ breast cancer was almost sixteenfold increased (SIR=15.98, 95% 
CI, 13.23-19.14). Poisson regression analyses showed that women with a family 
history of breast cancer had almost 50 percent increased risk of contralateral 
invasive breast cancer, compared to women without a family history of breast 
cancer (adjusted incidence rate ratio =1.47,  95% CI, 1.05-2.05). 
Among women diagnosed with in situ breast cancer, the cumulative 10- and 20-
year risk for a subsequent ipsilateral or contralateral invasive cancer was 
approximately 10 and 18 percent respectively, while the cumulative 10- and 20-
year risk for a subsequent contralateral in situ breast cancer was 1 and 2 percent 










Table 6.2 Standardized incidence ratio (SIR) of second breast event (contralateral in situ or ipsilateral or contralateral invasive breast cancers) 












* Reference group is No family History. Incidence rate ratio has been adjusted for attend age, calendar period, age and year of first diagnosis of 
carcinoma in situ and time since first diagnosis 
† background rate of in situ breast cancer was divided by 2 




 All No family history Family history  Incidence 
Rate 
Ratio* 
(95% CI)  
No. of  
cases 
SIR  








(95 % CI) 
2nd 
breast cancer† 886 
5.08        
(4.75,5.43) 781 
4.95        
(4.61,5.31)  105 




2nd  in situ 
Contralateral† 118 
15.98       
(13.23,19.14) 104 
15.80       
(12.91,19.15) 14 
17.44        
(9.54,29.26)




+contralateral       
+missing side 768 
4.55        
(4.23,4.88) 677 
4.40        
(4.07,4.74) 91 







4.26        
(3.84,4.72) 334 
4.19        
(3.75,4.66) 42 
4.97        
(3.58,6.72) 




3.42        
(3.05, 3.83) 262 
3.28        
(2.89,3.70) 41 
4.82        
(3.46,6.54) 




Figure 6.1 Cumulative incidence of second breast event among women diagnosed 
with in situ breast cancer, stratified by types of subsequent breast events. 
 
 
Women with in situ breast cancer with no family history experienced an increasing 
SIR of a subsequent invasive cancer during the study period, SIR 3.09 (95% CI, 
2.42-3.89) in 1980-1984, versus SIR 5.05 (95% CI, 3.88-6.46) in 2000-2004 (P-
trend <0.001). In contrast, for women with a family history, SIR of a subsequent 
invasive breast cancer remained relatively high over the study period (Table 6.3). 
The EAR also increased over the study period for women with no family history 
but not for women with a family history (Table 6.4). 
Overall, the relative risk for a subsequent invasive breast cancer was almost twice 
as high for women under forty at first in situ breast cancer diagnosis compared with 
women over forty, SIR 8.54 (95% CI, 6.07-11.67) and 4.44 (95% CI, 4.12-4.77) 
respectively (P-value <0.001). Among women below forty with a positive family 
history, the risk for a subsequent invasive cancer was more than fourteen times 
higher than in the general population, SIR 14.3 (95% CI, 7.39-24.99). Given that 





























EAR in relation to age at diagnosis. While the relative risk of a subsequent invasive 
breast event decreased with increasing age for both women with and without a 
family history for breast cancer, the overall EAR was similar for women below 
forty years at diagnosis (93.17 per 10,000 person-years, 95% CI, 63.42-129.84) as 
compared to women over forty (88.50 per 10,000 person-years, 95% CI, 80.41-
96.99) (Table 6.4). In contrast, women with a family history of breast cancer had 
higher EAR, with women under 40 years of age carrying the greatest EAR (154.10 
per 10,000 person-years, 95% CI, 77.14-266.30),  compared to women older than 
40 years at diagnosis (105.72 per 10,000 person-years, 95% CI, 78.88-136.82). This 
suggests that both relative and absolute risks are higher with younger age of onset 
of in situ disease in women with a positive family history.  
Finally, regardless of family history,  the risk for subsequent invasive cancer in the 
first five years after first in situ breast cancer was increased more than fivefold 
compared to the general population (SIR=5.20, 95% CI, 4.71-5.74). In women with 
no family history there was a significant decline in both the relative and absolute 





Table 6.3 Standardized incidence ratio (SIR) of second invasive breast cancer (ipsilateral and contralateral) after diagnosis of first in situ breast 
cancer, by year at first diagnosis, age at first diagnosis, time since first diagnosis and family history 
  Overall No Family History Family History 
  No. of 
cases 










1980-1984 81 3.31 (2.63,4.11) 72 3.09 (2.42,3.89) 9 6.58 (3.01,12.49) 
1985-1989 141 3.54 (2.98,4.17) 123 3.36 (2.79 ,4.01) 18 5.34 (3.16 ,8.44) 
1990-1994 292 5.23 (4.65,5.86) 259 5.12 (4.51,5.78) 33 5.90 (4.06,8.29) 
1995-1999 182 5.24 (4.51,6.06) 160 5.17 (4.40,6.04) 22 5.23 (3.28,7.92) 
2000-2004 72 5.11 (4.00,6.44) 63 5.05 (3.88 ,6.46) 9 5.48  (2.51,10.40) 






< 40 39 8.54(6.07,11.67) 27 7.20(4.75,10.48) 12 14.30 (7.39,24.99) 
40-49 173 4.88 (4.18,5.66) 147 4.85 (4.10,5.71) 26 4.70  (3.07,6.89) 
50-59 221 4.07 (3.55,4.65) 189 3.88 (3.35,4.48) 32 5.22  (3.57,7.37) 
60-69 220 4.57 (3.99,5.22) 207 4.53  (3.93,5.19) 13 5.16  (2.75,8.82) 
≥70 115 4.33 (3.58,5.20) 107 4.20  (3.45,5.08) 8 6.90   (2.98,13.60) 
P-trend  0.008  0.069  0.096 
 <40 39 8.54(6.07,11.67) 27 7.20(4.75,10.48) 12 14.30 (7.39,24.99) 
 >40 729 4.44 (4.12,4.77) 650 4.33 (4.00 ,4.67) 79 5.15  (4.08,6.42) 





0-4 401 5.20 (4.71,5.74) 359 5.13 (4.62,5.69) 42 5.45 (3.93,7.37) 
5-9 230 4.44 (3.89,5.06) 197 4.19 (3.62,4.82) 33 6.51 (4.48,9.15) 
10-14 96 3.42 (2.77,4.17) 85 3.31 (2.65,4.10) 11 4.28  (2.14,7.66) 
15+ 41 3.41 (2.44,4.62) 36 3.19  (2.24,4.42) 5 5.92 (1.92,13.82) 
P-trend  <0.001  <0.001  0.848 
* When the follow-up time was restricted to 5 years the estimates were similar but the trend tests not significant 
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Table 6.4 Excess additive risk (EAR) of second invasive breast cancer (ipsilateral and contralateral) per 10,000 person-years after diagnosis of 
first in situ breast cancer, by year at first diagnosis, age at first diagnosis, time since first diagnosis and family history 
  Overall 
 
No Family History Family History 














 1980-1984 81 52.75 (37.45,70.43) 72 48.28 (33.04,66.05) 9 110.89 (42.95,215.85) 
1985-1989 141 61.81 (48.36,76.82) 123 57.73 (44.05,73.13) 18 100.78 (51.95,167.20) 
1990-1994 292 107.88 (93.16,123.77) 259 105.83 (90.45,122.51) 33 116.53 (73.94,169.99) 
1995-1999 182 111.20 (92.24,132.08) 160 109.53 (89.57,131.67) 22 110.38 (61.01,175.62) 






< 40 39 93.17 (63.42,129.84) 27 77.90 (47.93,116.43) 12 154.10 (77.14,266.30) 
40-49 173 85.36 (70.19,102.11) 147 84.82 (68.47,103.03) 26 81.46 (46.61,126.48) 
50-59 221 83.61 (69.64,98.88) 189 78.20 (63.88, 93.94) 32 117.94 (73.05,174.48) 
60-69 220 98.46 (82.54,115.85) 207 96.87 (80.69,114.59) 13 121.1 (53.53,218.20) 
≥70 115 85.99 (66.78,107.69) 107 82.72 (63.43,104.60) 8 152.17 (55.54,305.46) 
 <40 39  93.17 (63.42,129.84) 27 77.90 (47.93,116.43) 12 154.10 (77.14,266.30) 
 >40 729 88.50 (80.41,96.99) 650 85.87 (77.50,94.67) 79 105.72 (78.88,136.82) 
 0-4 401 98.39 (86.87,110.69) 359 97.42  (85.34,110.38) 42 98.33 (65.49,138.51) 
    Time 
since 
diagnosis 
5-9 230 88.49 (74.36,103.89) 197 82.22 (67.83, 98.01) 33 137.92 (88.46,200.00) 
10-14 96 66.28 (48.77,86.29) 85 63.44  (45.47,84.15) 11 89.41 (33.33,172.54) 
15+ 41 69.06 (42.11,102.12) 36 62.90 (36.15,96.16) 5 143.72 (32.81,342.47) 
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Mortality risk  
The overall all risk of death in women with in situ was significantly increased, by 
30 percent compared to the general population but highly dependent on the 
occurrence of second invasive cancer event (Table 6.5). Women, who did not 
develop a second invasive event following in situ breast cancer, had a similar risk 
of death as the background population (SMR=1.01, 95% CI, 0.95-1.08). In contrast, 
women who were diagnosed with a second invasive event were twice as likely to 
die as compared to women in the general population (SMR=2.06, 95% CI, 1.72-
2.44) with no significant differences between women with and without a family 
history for breast cancer.   
The overall risk of death following an in situ breast cancer was increased for women 
with a family history (SMR=1.44, 95% CI, 1.15-1.78) as well as for women without 
(SMR=1.28, 95% CI, 1.21-1.35). Given that deaths were rare at younger ages we 
compared mortality among women above and below age 50 years. Women below 
age 50 years at first in situ breast cancer diagnosis and who were diagnosed with a 
second invasive cancer, had significantly higher mortality as compared to women 
over 50 years at diagnosis, (SMR=8.03, 95% CI 5.38-11.54 versus SMR=1.70, 95% 








Table 6.5 Standardized mortality ratio (SMR) of second breast event (contralateral in situ or ipsilateral or contralateral invasive breast cancers) 
after diagnosis of first in situ breast cancer and its 95% CI, by type of second breast event and family history. 
       *one subject had both ipsilateral and contralateral invasive breast cancer 
 All No family history Family history  <50 >50 
 No. of  
deaths 
SMR  
(95 % CI) 
No. of  
deaths
SMR  
(95 % CI) 
No. of  
deaths 
SMR  
(95 % CI) 
No. of  
deaths 
SMR  
(95 % CI) 
No. of  
deaths 
SMR  
(95 % CI) 










No event + 2nd 
contralateral 






















































































6.4 Discussion  
 
In this large population-based cohort, with data from nationwide, high quality 
registers, we demonstrated that women diagnosed with in situ breast cancer had a 
considerably increased risk for an invasive and contralateral in situ breast cancer, 
compared to women in the general population, with young women facing the 
highest risks. Having a positive family history increased the risk for a contralateral 
invasive breast cancer by 50 percent compared to not having a family history for 
breast cancer. The increased risk for an invasive cancer persisted over time and still 
fifteen years after diagnosis, the risk was three times higher than in women in the 
general population. Meanwhile, the mortality for women with in situ breast cancer 
was the same as the general population, as long as an invasive cancer did not occur.  
In women diagnosed with breast carcinoma in situ and with a positive family history, 
the risk of a contralateral invasive breast cancer was four times higher than women 
in the general population. It is 1.5 times higher compared to women with in situ 
disease but without family history.  There are methodological issues that may 
account for these differences, since our estimates assume only one breast is at risk, 
with a corresponding lower expected rate. Two meta-analyses of familiar risks for 
breast cancer presented the relative risk associated with having a first degree 
relative of breast cancer to be 2.1 and 1.8, respectively [28, 306]. The observed 
diluted additional risk in women with a family history, i.e. only 50 percent increased 
risk for a contralateral invasive cancer, and no increased risk for ipsilateral invasive 
cancer or contralateral in situ cancer, as compared to non-family history women, is 
intriguing.  We speculate that women with a positive family history were likely 
more prone to choose mastectomy than those without family history, which would 
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reduce the risk for an ipsilateral cancer in these women. The reduced risk may also 
be a reflection of heterogeneity of the in situ breast cancer phenotype. Additional 
stratification into one, two or even three affected first-degree members to better 
quantify the hereditary component may have allowed a deeper understanding of 
these results.  
Regardless of family history, women under forty years of age at diagnosis had a 
significantly higher risk for subsequent invasive breast cancer compared to women 
above forty years. These young women would experience an absolute excess risk 
ranging from about 8 events per 1,000 person-years to as high as 15 events per 
1,000 person-years depending on family history, this absolute excess risk decreases 
with increasing age only for women with a positive family history. Given that 
young women with family history have much higher risk for a subsequent event, 
studies on best treatment options such as mastectomy versus breast conserving 
surgery may be needed for this group of patients.  
The increased relative risk for subsequent invasive breast cancer by almost 60 
percent from 1980-84 to 2000-04, exclusively in women with no family history, 
may be related to a combination of screening and treatment patterns. During the 
study period, nationwide mammography screening was introduced, which had a 
complete national coverage by 1997 [307]. With increasing mammography 
screening and subsequently a larger number of detected smaller lesions, the 
majority of whom are non-palpable, the use of breast-conserving surgery has 
become the norm from 1990 onwards [308]. In comparison to mastectomy, breast-
conserving surgery poses an increased risk for both local recurrence and new 
ipsilateral primary cancers. In contrast, women with a positive family history had 
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no increased risk during the study period and we speculate that these women, who 
had relatives with breast cancer, were more prone to choose mastectomy.  
During follow-up, women with no family history of breast cancer had a gradually 
decreasing risk for subsequent invasive breast cancer with time since diagnosis. 
However, still 15 years after first in situ breast cancer, the risk for an invasive breast 
cancer was almost three times higher than for women in the general population. 
This indicates that women diagnosed with in situ breast cancer have a lifelong 
increased risk, which needs to be taken into account for when planning their follow-
up. 
Overall, there was no increased risk of death for women with in situ breast cancer 
as long as a second invasive event did not occur, but in women with a second 
invasive breast cancer the risk of death was doubled. There were no significant 
differences in mortality between women with and without family history. Young 
age of onset was an important predictor of death for women with in situ disease due 
to an increased risk for second invasive cancers and thus a substantially higher 
mortality, which should be taken into account when planning their treatment and 
follow-up.  
Strengths of the current study include the population-based design, its large sample 
size, complete follow-up and unbiased ascertainment of family history, cancers and 
death. To the best of our knowledge, this is the largest study to assess the impact of 
a positive family history for breast cancer on risk and mortality after in situ breast 
cancer.  
This study has a number of limitations. We have not distinguished between 
mastectomies and breast-conserving surgery, and ductal carcinoma in situ breast 
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cancer and lobular carcinoma in situ breast cancer.  With this stated, a previous 
Swedish case-control study has shown that the risk for a subsequent invasive breast 
cancer was equal after lobular and ductal carcinoma in situ breast cancer [300]. Due 
to regional differences in how to report second ipsilateral in situ breast cancer, such 
events were not included in the study. 
In conclusion, a positive family history increases the risk only for a contralateral 
invasive breast cancer among women with in situ breast cancer. The risk for a 
subsequent invasive breast cancer, as well as mortality is substantially higher in 




Chapter 7 Validation of the CancerMath prognostic tool for 




Adjuvant chemotherapy and hormone therapy improve long-term survival and 
reduce the risk of recurrence in early breast cancer patients [147, 309, 310].  
However, the benefit varies greatly from patient to patient due to biologic 
heterogeneity of the disease and differences in response to treatment [164, 311].  
Risk of adverse effects and high cost of adjuvant therapy also make it challenging 
for oncologists to choose the most appropriate treatment. Therefore, several clinical 
tools have been developed to predict prognosis and survival benefit from treatment, 
using clinical and histological features, genetic profiles, and novel biomarkers [185].   
CancerMath (http://www.lifemath.net/cancer/) is the latest web-based calculator to 
estimate overall survival for each of the first 15 years after diagnosis [189]. It also 
provides information on conditional survival (the likelihood of surviving given 
being alive after a certain number of years), probability of positive lymph nodes, 
and nipple involvement as well as benefit of systemic treatment.  However this new 
tool has not been validated outside the United States. The aim of the study is to 
validate this model in the Singapore Malaysia Hospital Based Breast Cancer 
Registry, demonstrating its predictive performance for different subgroups and 








Women diagnosed with pathological stage I to III breast cancer according to the 
sixth edition AJCC staging system, who underwent surgery, were identified from 
the Singapore Malaysia Hospital Based Breast Cancer Registry. Patients diagnosed 
until 31st December 2011 were followed up from date of diagnosis until date of 
death or date of last fellow-up, whichever came first. Date of last follow-up was 1st 
March 2013 for UMMC, 31st July 2013 for NUH, and 1st October 2012 for TTSH.  
Male patients, patients with unknown age at diagnosis and tumor size were 
excluded from this analysis as these two were essential predictors for all four 
CancerMath calculators. 
Javascript code of all four CancerMath calculators which contained predetermined 
parameters for the predictors and mathematical equations was exported on 9th Nov 
2013 from its website by selecting “view-> source” in the browser menu. The script 
was then transcribed into R script to allow calculation for a group of patients. For 
nodal status calculator, patient’s age, tumor size, ER and PR status, histological 
type, and grade were used by the programme to calculate probability of positive 
nodes for each patient.  Overall mortality risk at each year up to 15 year after 
diagnoses was predicted by outcome calculator, based on age, tumor size, number 
of positive nodes, grade, histological type, ER, PR, and HER2 status.  Effect of 
hormone and chemotherapeutic regimen on overall mortality was further adjusted 
by the therapy calculator and number of years since diagnosis was taken into 
account in conditional survival calculator. Results from R script and website were 
crosschecked with a random subset of 20 patients to verify the accuracy of the R 
script.  Histological type recorded as others was re-categorized as unknown 
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histological type for calculation. If HER2 status was equivocal based on IHC and 
FISH was not performed, HER2 status was treated as unknown.  Evidence of 
recurrence was set as unknown for conditional survival calculation.   
 Only cases with known nodal status (N=6807) were included for validation of 
nodal status calculator and their individual probability of positive lymph nodes was 
calculated. For outcome calculator,  two separate subsets of patients with minimum 
5-year follow up (UMMC and NUH patients diagnosed in 2007 and earlier and 
TTSH patient diagnosed in 2006 and earlier, N=4517) and patients with 10-year 
follow-up (UMMC and NUH cases diagnosed in 2002 and earlier, N=1649) were 
selected for comparison of observed and predicted survival. As NUH and TTSH 
did not collect details of hormone therapy and chemotherapy regimen data, therapy 
calculator was only validated for UMMC patients with minimum 5-year follow up 
(N=1538).   
Statistical analysis 
Nodal status calculator  
Observed and predicted probabilities of positive lymph nodes were compared. 
Calibration was assessed by plotting the observed probability of positive nodes 
against median of predicted probability for each decile of the predicted probability. 
Discrimination of predicted probability of nodal involvement was evaluated by 
AUC.   
Outcome and therapy calculator  
Ratio of observed and predicted numbers of death within 5 years and 10 years of 
diagnosis were calculated as mortality ratio (MR) with 95% CI constructed by exact 
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procedure [312].  MR was also calculated for different subgroups by country, period 
of diagnosis, age, race, and other clinical characteristics.  Actual 5-year and 10-year 
survival rates were estimated by Kaplan-Meier analysis (observed survival), and 
compared with median CancerMath predicted survival.  A difference of less than 
3% would be considered reliable enough for clinical use as 10-year survival benefit 
of 3-5% is an indication for adjuvant chemotherapy [207].  The relationship of the 
predicted and observed 5-year and 10-year survival was also demonstrated by the 
calibration plot for the outcome and therapy calculator.  Discriminative ability of 
predicted 5-year survival and 10-year survival from outcome and therapy calculator 
was evaluated by AUC using dataset with minimum 5-year and 10-year follow-up 
accordingly.  Outcome calculator was further evaluated by C-statistics for the entire 
dataset regardless of follow-up time.   
Conditional survival calculator  
For patients who survived two years after diagnosis, predicted 5-year survival was 
compared with observed 5-year survival.  Similarly predicted 10-year survival was 
compared with observed 10-year survival for patients who survived 5 years and 7 
years respectively.  Discriminative ability was evaluated by AUC.   
7.3 Results  
 
In total, 7064 female breast cancer patients were included.  Tables 7.1-7.4 present 
clinical characteristics of 6807 patients with nodal status, 4517 patients with 
minimum 5-year follow-up, 1649 patients with 10-year follow-up, and 1538 




Nodal status calculator 
A total of 6807 patients with nodal status data were selected for validation of nodal 
status calculator.  In this dataset, 43.6% patients (n=2970) had at least one positive 
lymph node and the median predicted probability was 40.6%. In fact, cancerMath 
underestimated the probability of positive node for most of the subgroups (Table 
7.1). The calibration plot (Figure 7.2) also illustrated underestimation except for the 
last two deciles of predicted probability. The discriminative ability of this calculator 















Table 7.1 Observed number of patients with positive lymph nodes and predicted 
probability of positive nodes among breast cancer patients. 
 Number of patients with positive 
lymph nodes (percentage)  
Predicted probability of 
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822   (28.1%) 
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662   (50.3%) 
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1278 (45.1%) 
1275 (51.8%) 








Figure 7.1 Histogram of CancerMath predicted probability of positive nodes 




Figure 7.2 Calibration plot of observed probability of positive nodes with 95% 
confidence interval against predicted probability of positive nodes (median) by 
































Predicted probability of positive nodes from CancerMath
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Outcome calculator  
The observed number of deaths within 5 years after diagnosis was significantly 
higher than the predicted number of deaths (752 vs 667, MR=1.13, 95% CI 1.05-
1.21).  The number of observed and predicted number of deaths within 10 years 
after diagnosis was not significant (488 vs 454, MR=1.07, 95% CI 0.98-1.17).  The 
absolute differences of 5-year and 10-year predicted and observed survival 
probabilities were 3.9% and 4.9%.  Overestimation was more pronounced in 
Malaysian patients than in Singaporean patients (5.8% vs 2.5% for 5-year survival, 
and 8.0% vs 0.0% for 10-year survival).   We also observed notable differences for 
cases diagnosed in earlier period and of younger age (Table 7.2 and 7.3).  In addition, 
CancerMath significantly overpredicted survival for patients with unfavorable 
prognostic characteristics such as large tumor size, more positive nodes and ER 
negative tumor. For those with relatively better predicted survival, CancerMath 
predictions were similar to observed outcome (Figure 7.5 and 7.6).  For example, 
the difference between 5-year predicted and observed survival was 17%, 3% and 1% 
for the first, fifth, and tenth deciles respectively. The AUC for 5-year and 10-year 
overall survival were 0.77 (95% CI, 0.75-0.79) and 0.74 (95% CI，0.71-0.76), 
respectively whereas the C-statistics was 0.74 (95% CI, 0.72-0.75).  Both measures 






Table 7.2 Observed and predicted 5-year overall survival from outcome calculator, stratified by patients’ characteristics 
































































































































































































70+ 406 129 117 1.10(0.92,1.31) 68.2 (0.023) 73.9 5.7 (1.2,10.2) 




































































































































































































































































































Table 7.3 Observed and predicted 10-year overall survival from outcome calculator, stratified by patients’ characteristics 


































































































































































































































































































































































































































































































Figure 7.3 Histogram of CancerMath predicted 5-year survival among 4517 




Figure 7.4 Histogram of CancerMath predicted 10-year survival among 1649 




Figure 7.5 Calibration plot of observed survival with 95% confidence interval 
against predicted  survival (median) by deciles of the predicted value for 5-year 
survival from outcome calculator 
 
 
Figure 7.6 Calibration plot of observed survival with 95% confidence interval 
against predicted  survival (median) by deciles of the predicted value for 10-year 



















































Predicted 10-year survival from CancerMath outcome calculator
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Therapy calculator   
For the therapy calculator which was only validated in Malaysian patients, 
predicted survival was significantly higher than the observed survival for almost all 
subgroups, except for those diagnosed recently and with more favourable tumor 
characteristics (Table 7.4, Figure 7.7). The calculator showed fair discrimination at 
5-year overall survival (AUC=0.73, 95% CI 0.70-0.77). 
Conditional survival calculator  
For patients who have survived 2 years since diagnosis, the predicted 5-year 
survival was 91.0% versus the observed survival of 88.3%.  The AUC was 0.75 
(95%CI, 0.73-0.77).  For patients who have survived 5 years and 7 years, the 
predicted probability of surviving up to 10 years was 86.6% and 91.7% respectively.  
And the observed survival was 85.3% and 91.0% respectively.  The AUC was 0.66 













Table 7.4 Observed and predicted 5-year overall survival from therapy calculator, stratified by patients’ characteristics 
 N Observed 
death in 5 
years 
Predicted 
death in 5 
years 



































































































































































































































































































































































































































































































































































Figure 7.7 Calibration plot of observed survival with 95% confidence interval against predicted survival (median) by deciles of the predicted 








































Predicted 5-year survival from CancerMath therapy calculator
115 
 
7.4 Discussion  
 
Many prognostic tools have been developed over the past two decades to aid clinical 
decision making for breast cancer patients. This study validated four different 
prognostic calculators provided by CancerMath in the Singapore Malaysia Hospital 
Based Breast Cancer Registry.  The discrimination was fair for nodal status 
calculator. CancerMath outcome, therapy and conditional survival calculator also 
moderately discriminated between survivors and nonsurvivors at 5 years and 10 
years after diagnosis.  It however consistently overestimated survival for this cohort 
of Southeast Asian patients, especially for those with poor predicted prognosis, as 
assessed by the calibration plot.   
CancerMath was previously built and validated using SEER data and patients 
diagnosed at Massachusetts General and Brigham and Women’s Hospitals [189].  
It was shown to be highly accurate and the difference between observed and 
predicted survival was within 2% for 97% of the patients in the validation set [189].  
Our study is the first one to independently validate CancerMath outside its initial 
study population and is also the largest validation study of a Western-derived breast 
cancer prognostic model in Asia.  We demonstrated that CancerMath overpredicted 
survival by more than 3% for almost all clinical and pathological subgroups.  The 
findings were similar to previous validation studies of Adjuvant! Online conducted 
in Asia.  In the Malaysian, Korean, and Taiwanese studies, the predicted and 
observed 10-year overall survival differed by 6.7%, 11.1%, and 3.9% 
correspondingly [197-199]. The AUC was 0.73 (95% CI, 0.69- 0.77) in the 
Malaysian study and hence very close to the AUC of CancerMath reported in the 
present study [197].  Furthermore the prediction was too optimistic for young 
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patients in almost all validation studies of Adjuvant! Online [193, 196-198].  
Although adjustment of 1.5-fold increase in risk was added to Adjuvant! Online 
version 7.0 for patients younger than 36 years and with ER positive breast cancer 
as stated in its help files, overprediction was still found in recent validation studies 
[193, 197, 198].  Our findings from current validation of CancerMath also suggest 
that correction for young age at diagnosis is needed.   
The selection of patients for validation can partially explain the discrepancy in 
observed and predicted survival. CancerMath has only been validated among 
patients with tumor size no more than 50mm and positive nodes no more than seven 
[313].  In our validation dataset, 10% of patients had tumor size larger than 50mm 
and 8% had more than ten positive nodes.  However even for patients with tumor 
size in between 20mm and 50mm and one to three positive nodes, the difference 
between the predicted and observed survival was more than 3%.  In general, Asian 
patients are more likely to present with unfavorable prognostic features such as 
young age, negative hormone receptor status, HER2 overexpression, and more 
advanced stage  compared to their western counterparts [102, 314, 315].  In our 
current analysis, reduced agreement was observed for patients with poorer outcome 
as illustrated by the calibration plot.  CancerMath also performed poorly in 
Malaysian patients than Singaporean patients due to higher proportion of patients 
in advanced stages in Malaysia [316].  Such limitation of CancerMath may restrict 
its use to patients with better prognostic profile only. Furthermore CancerMath 
therapy calculator applies the same amount of risk reduction from adjuvant therapy 
as Adjuvant! Online, which was estimated from meta-analysis of clinical trials 
mainly conducted in the Western population [147, 188, 189, 310].  However non-
adherence to treatment is more common among Asian women [317-322].   Studies 
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also reported different drug metabolism and toxicity induced by chemotherapy 
between Asian and Caucasian patients [323].  These evidences may imply 
CancerMath overestimate the effect of treatment in Asian patients.  
Another possible explanation of suboptimal performance of CancerMath and also 
the limitation of our study would be missing data on ER (6%), PR (15%), HER2 
status (47%), and tumor grade (11%).  For patients with complete information on 
required predictors (N=1872), the predicted and observed 5-year survival was 86.0% 
and 82.5%.   The difference was similar to what we observed in the entire dataset.  
Therefore the impact of missing data is relatively small on performance of 
CancerMath.  
Several gene expression profiling assay, such as MammaPrint [105] and Oncotype 
Dx [106] are currently available in the market for breast cancer prognostication and 
treatment decision. However these tools do not incorporate clinical and histological 
factors which are readily available or relatively cheap to obtain. Due to the high 
cost of these tests and larger proportion of patients with high predicted risk in Asia 
[324, 325], the clinical utility is uncertain in this region.  Therefore traditional 
prognostic model using clinicopathologic factors seems more reasonable in our 
local setting.  
In conclusion, we found that the discriminative ability and calibration of 
CancerMath calculators was modest in Southeast Asian patients.  Our results 
suggested that CancerMath was more suitable for patients diagnosed with 
favourable disease and received adequate treatment.   
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Chapter 8 Predicting survival of de novo metastatic breast cancer 
in Asian women: Systematic review and validation study of 
prognostic tools 
Originally published by PLoS One. [Miao H, Hartman M, Bhoo-Pathy N, Lee SC, 
Taib NA, Tan EY, Chan P, Moons KG, Wong HS, Goh J, Rahim SM, Yip CH, 




Asian women are more likely to be diagnosed with late stage disease compared to 
their Western counterparts. Approximately 10% to 25% of Asian breast cancer 
patients present with de novo metastatic disease, compared to 3% to 5% in Europe 
and United States [315, 326-329]. In addition,  metastatic lesions  in Asian women 
are larger and often involve multiple sites [200]. 
Metastatic breast cancer is incurable. Median survival rates range from one to four 
years, but on an individual level, survival times of up to 15 years have been reported 
[330-337]. While recent studies suggest that surgical removal of primary breast 
tumor has a positive impact on the survival of de novo metastatic patients [145, 338, 
339], systemic therapy, is the main treatment. Due to advances in locoregional and 
systemic treatment and due to the detection of small, solitary metastases, survival 
has improved over time, especially in patients with hormone receptor-positive 
tumors [334, 337].  
Accurate assessment of individual prognosis of patients with de novo metastatic 
breast cancer is needed for treatment decision making. In addition, like all patients 
with cancer, women with distant metastases want to know their prognosis [340]. As 
clinicians are known to be overoptimistic in predicting survival [341], prediction 
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rules can be useful for this heterogeneous group of patients with different treatment 
options. Although many multivariable prognostic indices have been developed for 
breast cancer in the last two decades, the majority are not applicable to patients with 
de novo metastatic disease [187-189]. In this study, we aim to identify prediction 
tools which can be used for prognostication of patients with de novo metastatic 
breast cancer and externally validate their performance in the Singapore Malaysia 
Hospital Based Breast Cancer Registry.  
8.2 Methods 
 
Systematic review  
Our first step was to perform a systematic review of the available literature, 
according to the PRISMA guidelines [342]. A free text search was performed on 13 
August 2013 to identify eligible studies using MEDLINE and EMBASE electronic 
database. Our search strategy included search terms and synonyms for prognostic 
models and the following string was used:  ((metastatic breast cancer) AND 
((prognostic scor* OR prognostic index OR nomogram OR predictive model OR 
validation OR validate OR prognostic model OR predictor) AND (scor* OR index 
OR model OR predict* OR nomogram OR validat*))) NOT (expression profiling 
OR microarray* OR proteomic OR affymetrix).  After reviewing the titles and 
abstracts, full text was selected applying predefined inclusion and exclusion criteria. 
Included were studies presenting multivariable models, with the aim to predict 
overall survival of metastatic breast cancer patients.  We excluded animal models 
or clinical trials on treatment efficacy, as well as studies which used disease-free, 
progression-free survival or response to treatment as the only outcome of interest. 
Etiological studies which only assessed the effect size of one specific prognostic 
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factor or only evaluated the prognostic value of a single biomarker were not 
included.  We also excluded prediction tools developed for patients with metastases 
from various primary cancers. Prognostic tools for patients with advanced cancer 
nearing the end of life or tools specific for recurrent metastatic breast cancer were 
not included as these patients have been exposed to multiple chemotherapy 
regimens and are often treatment resistant. Two studies which validated previously 
published models in metastatic breast cancer patients were excluded.  Additional 
articles were retrieved by cross-referencing.  Details regarding the author, year of 
publication, study design, model variables and performance measures were 
extracted if available. Quality of the selected publications was assessed using items 
listed in the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement, which were relevant to our study [343].  
Validation set  
Patients diagnosed with de novo metastatic breast cancer between 2000 and 2010 
were retrieved from Singapore Malaysia Hospital Based Breast Cancer Registry.  
They were followed up from the date of diagnosis until the date of death or date of 
last contact whichever came first. The date of last contact was 1 November 2010 
for UMMC patients, 1 July 2011 for NUH patients and 1 October 2012 for TTSH 
patients.  
Statistical analysis  
In the validation set, we investigated the pattern of missing data and assumed that 
data missingness was related to at least one other variable but not dependent on 
value of the observation itself, i.e. missing at random [344].  A total number of 230 
(36%) individuals had complete data on all variables used in validation and 90 (14%) 
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cases had 3 or more variables missing. On average, each individual had 1.13 
variables missing (standard deviation=1.22), ranging from 0 to 5. Missing values 
were imputed once using regression imputation [344].    
For each individual patient, we calculated the prognostic score for the different 
prognostic models/indices except for those developed by recursive partitioning 
analysis [345] and artificial neural network [346], as terminal nodes were missing 
in our dataset or algorithm was not provided to allow calculation of prognostic 
scores. For models including performance status, a variable that was not captured 
in our database, we assumed all patients to be fit at the time of diagnosis, i.e. 0 on 
Zubrod scale, which is the same as the Eastern Cooperative Oncology 
Group (ECOG) and the WHO scale, and 100 on the Karnofsky performance status 
(KPS) scale.  In order to check this assumption, we retrieved comorbidity data from 
the medical records of a subset of 87 NUH patients who diagnosed after 2006. We 
also assumed the best case scenario for lactate dehydrogenase (LDH). For brain 
metastasis models, a score of zero (best case scenario) was assigned to the largest 
brain metastasis dimension in Marko et al.’s model.  We assumed no trastuzumab 
use for HER2 positive patients in Ahn et al.’s model, as in Singapore and Malaysia 
trastuzumab use was rare during the time of our study. Since our study population 
consisted of patients who were metastatic at presentation, disease free interval was 
set as zero for all women.  
The distribution of each prognostic score was then divided into tertiles with the 
exception for Rabinovich’s model, for which were only two possible combinations. 
We compared the survival of low, intermediate and high-risk score patients by 
plotting the Kaplan-Meier survival curves for each tertile.  Median survival and 95% 
CIs were obtained for different groups and differences were tested by log-rank test 
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and log-rank test for trend. The discrimination ability of the models was assessed 
by C-statistic. For models with C-statistic larger than 0.6, 1-year, 2-year and 3-year 
cumulative survival probabilities were plotted for each quintile of the prognostic 
score.  
 
8.3 Results  
 
Systematic review  
The search strategy resulted in 1298 titles (Figure 8.1). Forty-eight full text articles 
were selected after screening the titles and abstracts and two articles were added by 
cross-referencing. A total of 16 prognostic indices met our inclusion criteria. Eight 
models were developed for patients with metastatic breast cancer in general, seven 
for patients with brain metastasis from breast cancer and one for breast cancer 
patients with metastatic spinal cord compression [347-362]. All prognostic indices 
were designed for both de novo and recurrent metastatic breast cancer patients 
(Table 8.1).  Study sizes ranged from 83 to 619 patients, with a median study size 
of 246 patients. The median survival from time of detection of metastasis ranged 
from 9.6 to 22 months. Cox regression incorporated time-to-event data and all-
cause mortality as outcome was used for model development in 13 studies. Three 
studies conducted recursive partitioning analysis and one used artificial neural 
network.  For Cox regression modeling, forward or backward stepwise selection 
with different cut-off P-values, either 0.05 or 0.1 was applied to identify final 
predictors.   
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Performance status, ER status, metastatic site(s) and disease free interval were the 
most common prognostic factors included in the different models. Performance 
status was measured on different scales, i.e. five studies used Zubrod/ECOG/WHO 
score while six models for brain metastasis used KPS [348, 350, 352, 354, 356-362]. 
Model coefficients or hazard ratios were presented in all Cox regression models.  
Six studies transformed the model into a scoring system for easy calculation of 
predicted survival and three studies developed a nomogram [347, 351, 352, 354, 
356-359, 362].  Recursive decision tree was constructed from recursive partitioning 
analysis in two studies [363, 364].  Only five studies evaluated the discrimination 
of their models using C-statistic or AUC [350, 353, 354, 358, 359], which ranged 
from 0.67 to 0.74 (moderate discrimination). Calibration was assessed by plotting 
predicted versus observed survival for only two models, which turned out to be well 
calibrated [358, 359]. Four studies conducted internal validation using random 
subset of data, ten-fold cross-validation and bootstrapping with 200 and 1000 
resamples [353, 358, 359, 362, 364]. Temporal validation of the model using data 
collected from the same hospital but later than those in the development set was 
conducted in four studies [348, 350, 352]. Five models were externally validated in 
other hospitals or outside the original country [351, 354, 358, 359, 363]. Quality of 







Figure 8.1 Flow chart of study selection process. 
n = number of studies. 
 
Titles identified from PubMed 
searching 
(n=1298) 
Abstract screened (n=177) 
Excluded by title review (n=1121) 
Full-text articles screened (n=48) 
Excluded by abstract review (n=129) 
Excluded by article review (n=34) 
 No prediction model/index 
developed (n=9) 
 For any cancer, validated in 
breast (n=4) 
 For any cancer, not validated 
in breast (n= 15) 
 Validation studies of models 
for breast cancer (n=2) 
 Other reasons (n=4) 
Models/indices included in 
review (n=16) 
Models/indices validated (n=9) 




 Table 8.1 Study characteristics of prognostic models for metastatic breast cancer patients 









Predictors  Analysis Discrimination Validation  
Nash et al. 1980 138 USA Single 
institution 




Not reported No 
Hortobagyi  
et al. 
1983 619 USA Single 
institution 
1973-1976 22 months LDH, PS,site(s) of 
metastasis, 
radiotherapy, 




Not reported  Temporal  
Williams et 
al. 






1974-1984 Not reported Grade, ER status, 









1992 362 Argentina Multiple 
institutions 













21.5 months adjuvant 
chemotherapy, 
presence of distant 





Not reported External 
Ryberg et al. 2001 469 Denmark single 
institution 
1983-1992 14.7 months Metastatic site(s),  
LDH, age, ER 
status and PS  
Cox 
regression 
Not reported  Temporal 
Giordano et 
al.  
2011 311 USA Single 
institution 
2004-2009 34.0, 28.3, 
20.5 and 8.1 
months for 
four risk 















therapy type, line of 




2013 236 USA Single 
institution 
2002- 2009 Not reported age, hormone 
receptor and HER2 
status, visceral 






External   
Le Scodan et 
al. 





1998-2003 5 months RTOG RPA, 





Not reported No 



















Not reported No 
Sperduto et 
al. 





1993-2010 13.8 months KPS, age, ER, PR 




Not reported External  





2000–2008 9.6 months KPS, extracranial 
metastases, age,  
trastuzumab, ER, 














1999-2008 16.2 months age, KPS, Non-











ER, PR, HER2, 
breast cancer stage 
Le Scodan et 
al. 










RPA Not reported No 
Niwińska et 
al. 









RPA Not reported No 














1995-2011 Not reported PS, ambulatory 








Not reported  Internal 
Abbreviation:   LDH,  Lactate dehydrogenase; PS, Performance status (Zubrod/ECOG/WHO score);  ALKP, alkaline phosphatase;  DFI, disease 
free interval;  KPS, Karnofsky performance score; CNS, Central nervous system;  ER, Estrogen receptor;  PR, Progesterone receptor; HER2, 








Table 8.2 Summary of quality assessment of publications selected for validation (Y, yes (presented in study) 






















Nash et al. Y   Y Y   
Hortobagyi  et al.  Y Y Y Y  Y 
Williams et al. Y Y Y    Y 
Rabinovich et al. Y Y Y Y Y Y Y 
Yamamoto et al.  Y Y Y Y  Y 
Ryberg et al.   Y  Y  Y 
Giordano et al. 
2011 
Y  Y  Y Y Y 
Giordano et al. 
2013 
Y Y   Y Y Y 
Le Scodan et al. 
2007 
Y Y Y Y Y   
Nieder et al. Y   Y Y   
Sperduto et al. Y Y Y Y Y  Y 
Ahn et al. Y Y Y  Y Y Y 
Marko et al. Y Y Y  Y Y Y 
Le Scodan et al. 
2012 
Y Y Y  Y   
Niwińska et al.  Y Y  Y   




Our validation set included 642 Asian de novo metastatic breast cancer patients with 
a median age of 53 years (range, 24-94).  Patient characteristics are reported in 
Table 8.3. Over a follow-up period of 1267.6 person-years, 492 patients had died 
and the median survival time was 19 months (95% CI, 16.5-21.5).  The 1-year, 2-
year and 3-year survival rates were 62%, 43% and 31% respectively.  Half of the 
patients had more than one metastatic site involved and the majority did not receive 
any surgery or radiotherapy. Chemotherapy and hormone therapy were 
administered to 53% and 32% of the study population respectively.  Among the 87 
NUH patients with comorbidity data, hypertension (30%) and diabetes (23%) were 
the most common medical conditions. Less than 10% of this group was suffering 
from coronary heart disease (7%), stroke (2%), chronic obstructive pulmonary 
disease (3%) and renal failure (1%) and 6% of the patients have more than two 
comorbidities.  
We validated all models that used Cox regression, with the exception of the models 
developed by Hortobagyi et al., Giordano et al., Le Scodan et al. and Rades et al. 
because the key predictors alkaline phosphatase (ALKP), circulating tumor cell 
(CTC),  lymphocyte count and metastasis to spine were not available.  Only 
Williams et al.’s, Yamamoto et al.’s, Rabinovich et al.’s and Ryberg et al.’s models 
were able to significantly discriminate between different risk groups in terms of 
overall survival based on log-rank test (Figure 8.2).  The median survival for the 
low-risk group, intermediate-risk group and high-risk group classified according to 
Williams et al.’s model was 30 months, 21 months and 10 months respectively.  For 
Rabinovich et al.’s model with two possible combinations, the median survival was 
27 months and 16 months for the low and high risk groups. For Ryberg et al.’s 
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model, the median survival was 29, 17 and 10 months respectively for the three 
groups. However the log-rank for trend test was not significant for Yamamoto et 
al.’s model as the median survival was 17 months for the low risk group, 24 months 
for the medium risk group and 15 months for the high risk group.  
In our cohort, discrimination of the different models was poor to fair, with C-
statistics ranging from 0.51 to 0.63 (Table 8.4). The model with the highest 
discriminatory ability was the model developed by Williams et al. (C-statistic=0.63, 
95% CI 0.60-0.66), followed by Ryberg et al. (C-statistic=0.61, 95% CI 0.59-0.64). 
A notable decreasing trend of 1-year, 2-year and 3-year cumulative survival 
probabilities was observed for the five risk groups (quintiles, Figure 8.3).  For 
Williams et al.’s model,  the 3-year survival probabilities for the lowest and highest 
risk group were 49% (95% CI, 39%-58%)  and 10% (95% CI, 4%-16%) 
respectively.  For Ryberg et al.’s model, 3-year survival probabilities were 53% 











Table 8.3 Characteristics of de novo metastatic breast cancer patients identified at 
NUH, TTSH and UMMC, 2000-2010 
  UMMC NUH TTSH Overall 







Median Survival in 













Median age at 
diagnosis in years 
(range) 
 50      
  (24-83) 
53       
(28-80) 
58       
 (30-94) 
53     
(24-94) 
Median tumor size 
in mm (range) 
 100       
(5-300) 
40        
 (2-210) 
60         
(2-200) 
60      
(2-300) 
















 Indian 30  
(11.3%) 
12   
 (7.7%) 




 Others 0     
 (0.0%) 
11    
(7.1%) 




Grade 1 2     
 (0.8%) 
5      
(3.2%) 












































 Unknown 48  
(18.0%) 
2     
(1.3%) 




















 Unknown 99 
 (37.2%) 
2     
 (1.3%) 
10  
  (4.5%) 
111 
(17.3%) 
















 Equivocal  20  
  (7.5%) 
12  
  (7.7%) 






















 Lung only 45  11    30  86 
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(16.9%) (7.1%) (13.6%)  (13.4%) 
 Liver only 22   
 (8.3%) 
9      
(5.8%) 




 Brain only 5    
  (1.9%) 
2      
(1.3%) 




 Soft tissue 
only 
5     
 (1.9%) 
0     
 (0.0%) 
3    
  (1.4%) 
8  
 (1.2%) 
 Other organ 
only 
2     
 (0.8%) 
1     
 (0.6%) 












 Unknown 12  
  (4.5%) 
4     
 (2.6%) 
























    (0.0%) 
9     
 (5.8%) 




















 Unknown 1      
(0.4%) 






















 Unknown 55 
 (20.7%) 






















 Unknown 82 
 (30.8%) 
3    













Figure 8.2 Kaplan-Meier survival curves of low, intermediate and high-risk 
groups. Risk groups were defined by tertiles of risk scores of prediction models 
for patients with de novo metastatic breast cancer. 
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Table 8.4 Validation of selected models for prediction of survival of patients with 
de novo metastatic breast cancer 












Nash et al. 642 0.23-3.44 0.23-3.44 0.51 (0.48,0.53) 
Williams et 
al. 




642 0.80-2.38 0.80-1.05 0.55 (0.53,0.57) 
Yamamoto et 
al. 
642 0.00-6.33 3.33-6.33 0.50 (0.48,0.53) 
Ryberg et al.  642 0.00-50.00 0.00-25.00 0.61 (0.59,0.64) 
Nieder et al. 52c 0.00-5.00 1.00-3.00 0.55 (0.48,0.61) 
Sperduto et 
al. 
50b,c 0.00-4.00 1.50-4.00 0.56 (0.47,0.65) 
Ahn et al. 50b,c 0.00-325.00 0.00-138.00 0.56 (0.46,0.66) 
Marko et al. 52c 0.00-375.00 44.50-108.60 0.55 (0.45,0.64) 
a Patients with brain metastases excluded    
b Patients with equivocal HER2 status were excluded   
c Exclusively patients with brain metastasis  














Figure 8.3 1-, 2- and 3-year cumulative survival probability for different risk 
groups.Risk groups were defined by quintiles of risk scores of Williams et al.’s 
and Ryberg et al.’s model. 1st quintile is the group with the highest predicted 
survival probability and 5th quintile is with the lowest predicted survival 







































































8.4 Discussion  
 
Survival after de novo metastatic breast cancer, a relatively common condition 
among breast cancer patients in South East Asia, varies considerably. In this study, 
we showed that this highly variable prognosis can be predicted using currently 
available prediction rules, only to a certain extent in Asian patients. Overall, the 
prediction performance in the present series in Asia was not as good as in the 
original reports. Some of these prediction rules, which were identified through 
systematic review of the literature, used easily available clinical information such 
as age, hormone receptor status and site of metastasis. Some other models included 
biomarkers, which are not routinely available during the work up of breast cancer 
patients such as CTC and LDH.  
We validated nine of the models in our Asian dataset and found that two models 
performed moderately well. In fact, with basic clinical information, (i.e. grade, ER 
status and site of metastasis), these models were able to classify patients as high 
risk and low risk. Based on risk scores calculated from Williams et al.’s and Ryberg 
et al.’s models, which included simple freely available clinical information, the 
difference of 3-year survival probability between the highest and lowest quintiles 
was close to 40%. Still, there was substantial overlap between the categories, and 
the current prediction rules were at best fairly able to discriminate between low and 
high risk patients (highest C-statistic=0.63). Comparing to the other three models 
developed for all metastatic breast cancer patients, the models developed by 
Williams et al and Ryberg et al incorporated ER status and also grouped metastatic 
site into more categorizes. We were unable to validate the models which included 
advanced biomarkers, as this information was not routinely captured in our patients.  
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The inferior performance of the models in our Asian dataset as compared to the 
original report could be explained by unavailability of some predictors in our cohort 
and the fact that these indices/models were not specifically designed for de novo 
metastatic breast cancer. Another explanation could be that the Western derived 
models are not suitable for Asia setting. For example, in women with stage I-III 
breast cancer, Adjuvant!Online overpredicted survival by almost 7% and this 
overprediction was especially pronounced in younger women and women of Malay 
descent [197]. The underlying cause might be different distributions of age, tumor 
characteristics, competing risks and lifestyles factors. Several studies have reported 
that Asian breast cancer patients are more likely to be premenopausal, ER/PR-
negative and HER2-positive [102, 365, 366].  Such differences could result in more 
skewed or more restricted range of prediction scores (Table 8.4).  
Accuracy of predicting survival is crucial for women with de novo metastatic breast 
cancer as treatment varies widely, from no treatment at all, to removal of primary 
tumor and aggressive systemic treatment. The use of endocrine therapy and anti-
HER2 drugs has been shown to prolong survival of metastatic patients [367-369]. 
Many randomized control trials have also reported significant survival benefit from 
modern chemotherapeutic agents, such as taxanes [370].  Recent studies have 
suggested that women who undergo surgery for de novo metastatic breast cancer 
have a significantly lower risk of death as compared to those who do not [145, 338, 
339].  However the high proportion of patients not treated in our cohort or different 
response to treatment between Asian and Caucasian women may affect the 
usefulness of certain predictors such as hormone receptor status as well as the 
overall performance of the prediction models.  
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We acknowledge that our study suffers from limitations. The main limitation of the 
current study is the unavailability of certain clinical variables for prediction in our 
database such as performance status and LDH.  Performance status, either recorded 
in Zubrod/ECOG/WHO or KPS, is a significant predictor in 11 indices/models. 
According to the development studies, 60% to 79% of their study population in fact 
had good performance status (Zubrod/ECOG/WHO= 0 or 1 or KPS ≥70). Based on 
the results from a subset of patients with comorbidity data in our validation set, our 
assumption of patients to be generally fit may have resulted in some overestimation 
of predicted survival probabilities for a subset of patients. The number of CTC has 
been shown to be highly predictive for overall survival in patients with metastatic 
breast cancer [371, 372]. The CELLSEARCH test (Veridex, LLC, Raritan, NJ, USA) 
is the first and only clinically validated, FDA-cleared system for CTC assessment 
[373, 374]. However it is not routinely measured in Asia and is unlikely to be 
measured in future in low and middle income countries. The underperformance of 
models developed for brain metastasis maybe partially caused by the exclusion of 
non-treated patients in the development study, the lack of largest brain metastasis 
dimension and trastuzumab use in our validation dataset. Another limitation of our 
validation is the incomplete data of certain predictors. The pattern of missingness 
suggested missing at random and thus imputation was a better and more reasonable 
option than complete case analysis. The C-statistic for Williams et al’s model from 
complete case analysis of 297 patients with grade, ER status and metastatic site(s) 
was 0.63 (95% CI, 0.59-0.67), which was very similar to the result from imputation 
(0.63, 95% CI, 0.60-0.66). However the standard errors and confidence intervals of 




We conclude that existing prognostic models can only moderately predict survival 
of women with de novo metastatic breast cancer in the Asian setting. New models 
derived from a representative sample from an Asian population with different 
disease burden, would be able to accurately discriminate between patients with 





















Chapter 9 Overall discussion and future perspectives  
 
Clinicians and breast cancer patients have a keen interest in knowing the probability 
of survival and disease progression so that they can choose the most appropriate 
treatment, decide the frequency and intensity of post-treatment surveillance and 
plan for future activities. However there is no one-size-fits-all solution due to the 
heterogeneous nature of breast cancer.  Although classification systems based on 
histopathological or molecular features have been established for risk stratification 
and tailored management plan, differences in response to treatment and disease 
courses have been observed among patients with similar tumor profiles.  Without a 
clear picture of the biological and clinical diversity of breast cancer, we are nowhere 
near achieving individualized prognostication and treatment.   
This thesis focuses on outcome and prognostic factors in understudied subgroups 
of breast cancer patients:  male breast cancer patients, patients with breast 
carcinoma in situ, patients with de novo metastatic breast cancer, and patients from 
Southeast Asia. Comparison between male and female breast cancer, between 
diseased and healthy individuals in the first and second study helped us better 
understand breast cancer risk and progression.  Study of periodic trend of breast 
cancer outcome provided evidence on effect of early detection and treatment 
advancement. Identification of clinically important prognostic factors such as 
young age and family history for women diagnosed with carcinoma in situ would 
improve evidence-based decision-making.  Last but not least, validation of 
prognostic tools in Southeast Asia evaluated the clinical utility of these tools in this 




9.1 Male breast cancer 
 
Male breast cancer is a rare disease and treatment for male breast cancer typically 
follows the guidelines set for female breast cancer as it is considered resemble 
postmenopausal female breast cancer.  The first study in this thesis found that the 
improvement in survival among male breast cancer over the last 30 years was not 
as pronounced as female patients.  The poorer observed survival of male patients 
can be explained by older age at diagnosis, late stage and treatment differences. 
These findings suggest lack of early detection and specific treatment guidelines for 
men. Therefore it is important to raise public awareness of this rare disease and 
educate men on the early symptoms of breast cancer.  Studies have reported higher 
proportion of hormone receptor positive among male patients and mixed results on 
HER2 status.  However men with hormone receptor positive disease have 
reportedly poorer adherence to tamoxifen with 20% patients discontinuing due to 
side effects [375].  Most of these studies suffered from small sample size and 
variation in study designs and methods [376].  Since men are diagnosed with older 
median age, age, comorbidity and performance status should be carefully 
considered when determine chemotherapy with toxic adverse effects. In addition, 
data on treatment of male breast cancer is mainly from small retrospective and 
single institutional studies. Conducting RCT for male breast cancer is very 
complicated due to low incidence.  Unfortunately detailed treatment data such as 
compliance and regimes are not available in population-based cancer registries.  
Multi-institutional collaboration is crucial to understand tumor biology, effect of 
treatment and compliance to treatment, especially hormonal therapy on male breast 
cancer.  The ultimate goal is to formulate guidelines and protocols for treatment and 
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surveillance based on robust and consistent observations from large scaled 
prospective studies.  
9.2 Breast carcinoma in situ 
 
The risk of subsequent invasive breast cancer varies between patients as breast 
carcinoma in situ can either be an indolent non-progressive lesion which only 
requires close monitoring, or a precursor to invasive breast cancer which should be 
treated more aggressively using mastectomy or chemotherapy [377].  However 
carcinoma in situ patients are more likely to overestimate their risk of recurrence 
than early invasive breast cancer parents due to lack awareness about their 
prognosis [378].  This wrong self-perception on recurrence will eventually lead to 
anxiety and influence decision on treatment and long-term follow-up plan.  In the 
second study, we found that, among patients diagnosed with breast carcinoma in 
situ, family history increased the risk for a contralateral invasive breast cancer.  
Also women who diagnosed with breast carcinoma in situ before the age of 40 years 
were at higher risk of subsequent invasive breast cancer. Since mastectomy could 
lower the risk of local recurrence than breast conserving surgery, option of 
mastectomy should be discussed with young patients with family history.  
Meanwhile for patients with low risk of invasive event, overtreatment should be 
avoided.  There is lack of evidence on best post-treatment surveillance procedure 
for in situ cases.  A few recommendations have been proposed ranging from 
physical examination every 6 to 12 months to a mammogram every 6 to 12 months, 
especially during the first year of diagnosis and may vary by type of surgery 
received [379].  However these recommendations did not take young age at 
diagnosis and family history into consideration.  Findings from our study indicate 
146 
 
that patients with these risk factors should be monitored closely and continuously 
as the risk persists even 15 years after diagnosis.  For patients with low risk breast 
carcinoma in situ, there is an increasing interest in a watchful waiting or active 
surveillance approach which has been offered to prostate cancer patients to avoid 
treatment [380, 381].  There are two ongoing RCTs (LORD trial and LORIS trial) 
in the Netherlands and United Kingdom to compare the effect of active surveillance 
with the standard treatment for breast carcinoma in situ patients.  
The second study was conducted in Swedish population and its implication in Asia 
is uncertain.  Singapore is the first country to establish nationwide screening 
programme (Breast Screen Singapore) in Asia since January 2002 [382].  In 
Singapore breast screening pilot project, 26% of all screen-detected cancers were 
carcinoma in situ, which is much higher than 10–15% of cancers detected in women 
not invited for screening [383, 384].  With rising breast cancer incidence in 
Singapore and more women undergoing mammographic screening, in situ cancer 
is poised to become more common.  It is important to understand how introduction 
of screening could affect tumor characteristics and outcome of in situ disease in 
Singapore. Similarities and differences in the disease burden, pattern of 
presentation and outcome between ethnic groups in Asia and between Asian and 
Caucasian populations have not yet been studied.    
9.3 Prognostication for Southeast Asian patients  
 
In the past decades, we have witnessed a growing interest in, and use of, prognostic 
models in clinical decision-making process, especially in western countries.  
However validation studies of Adjuvant! Online conducted in Asia and validation 
of CancerMath conducted in this thesis have showed overestimation of prognosis 
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in this region by these prediction tools.  Existing models for metastatic breast cancer 
performed unsatisfactorily in this region as presented in the fourth study in this 
thesis. Many of these models were developed more than a decade ago and the more 
recent models included advanced biomarkers such as circulating tumor cell which 
is not obtained during routine clinical practice in Asia. Studies have revealed that 
breast cancer in Asian women is distinctive from their western counterparts in many 
perspectives such as underlying risk factors, disease presentation, tumor 
characteristics, lifestyle after cancer, treatment response and tolerance to side 
effects. The breast cancer epidemic in Asia calls for region-specific tools to improve 
outcome and treatment prediction. 
 In order to perform excellent research in the field of prognostication, complete, 
accurate and consistent longitudinal data collection is crucial, but this is not very 
easy to find (yet) in Asia.  The incidence rate of breast cancer in Singapore is among 
the highest in Asia and is steeply rising.  The availability of national and 
institutional cancer registries in combination with the multi-ethnic build-up of the 
society makes Singapore unique for validation of established prediction models and 
development of new models in an Asian setting.  Multi-institutional effort to set up 
the Singapore Malaysia Hospital Based Breast Cancer Registry was one of the 
initiatives to facilitate clinical research on breast cancer in Southeast Asia.  Thus 
far published and ongoing studies from this collaboration include validation of 
prognostic factors and models, comparison of outcome between ethnic groups and 
countries, evaluation of treatment effect and toxicity.  We anticipate more hospitals 
in this region to participate and more comprehensive data to be available for future 
studies.   
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Missing data and incomplete follow up are common problems in many retrospective 
clinical databases and become major obstacles for validation and development of 
prognostic models.  A substantial number of cases with follow-up less than 5 years 
were excluded in most analyses in study 3.  In study 4, we applied missing data 
imputation based on the assumption of missing at random.  Both approaches have 
their limitations, which may reduce the power of the study and potentially cause 
bias (reliability and validity of the findings).  This issue addresses the importance 
of prospective collection of data primarily for research purpose with clear definition 
and accurate measurement of outcome and covariates.    
9.4 Public health implications  
 
Prognostic and survivorship research for breast cancer is not highly recognized for 
its impact on public health as it focuses on tertiary prevention and only targets 
individuals affected by breast cancer.  Currently there are nearly 2.8 million women 
with a history of breast cancer living in the United States [385].  High prevalence 
of cancer survivors is associated with notable economic burden to the society, 
directly from increased medical expenditures and indirectly from productivity loss 
[386]. Given the increasing trend of breast cancer incidence and improvement in 
survival, Asian countries will expect more women living with the disease in the 
population.  Besides financial impact, risk of recurrence and secondary cancer, 
reduction in quality of life and wellbeing of family members and caregivers will 
soon become major public health concerns.   
Current public health efforts on cancer control such as promoting healthy lifestyles 
can be adapted for cancer survivors for early detection and prevention of recurrence 
and secondary cancer. Prognostic indicator or models can help us identify targeted 
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groups with high risk and formulate more personalized approach to deliver medical 
advice and care.   
Prolonging life is considered as a main goal when we evaluate effect of treatment 
or other interventions.  For high-income countries like Singapore with better 
healthcare facilities and cancer treatment but aging population, patient-reported 
outcome, which includes symptoms, functioning, health related quality of life and 
satisfaction with care after diagnosis and treatment becomes an important outcome 
measure in addition to survival. International efforts have been made in recent 
decades to develop patient-reported outcome measures (PROMs) for various types 
of cancer and establish guidance related to PROMs [387-390].  However robust and 
standardized PROM instruments specifically designed for breast cancer patients in 
Singapore is not yet available. Similar to prognostic models, many assessment tools 
were designed using Western population and the parameters included may not 
correctly address the health concerns of Asian patients.  Future studies on PROMs 
for breast cancer patients in Asia are needed.  
In contrast to high income countries with government-funded screening programme 
and medical subsidy for treatment, delayed presentation and poor compliance with 
treatment remain major concerns in many developing countries in Asia.  As a result, 
significant survival disparities between countries and between socioeconomic 
groups have been highlighted in many studies. Lack of awareness of breast cancer, 
poor access to quality healthcare facilities and health-seeking behaviour associated 
with cultural beliefs are the main barriers to better outlook for women with breast 
cancer.  The high cost and some technical limitation have hindered adaption of 
certain biomarker testing such as fluorescence in situ hybridization test for HER2, 
microarray based gene expression, circulating tumor cell, etc in local clinical setting.  
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Willingness and openness to discussion regarding life expectancy and survival 
probability in fact varies from patient to patient.  We need to consider these facts 
when developing new region-specific prognostic tool.  
Moving forward, the utility and cost effectiveness of prognostic markers or models 
should be evaluated using local data before adaption or making any modification.  
Ongoing data collection and biospecimen banking such as effort made by the 
Singapore Breast Cancer Cohort Study, which recruits existing and newly 
diagnosed breast cancer patients at five public hospitals in Singapore,   should be 
extended to other parts of the region to support large scaled clinical and translational 
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